DE102021004907A1 - Mechanochemically pretreated, heavy metal-free activated carbon particles A for use in medicine - Google Patents

Abstract

Heavy metal-free topical medicinal products for use in medicine, containing activated carbon particles (A) with a carbon content which have been mechanochemically pretreated under at least one inert gas and are free of heavy metals and persistent organic pollutants (POP), polycyclic aromatic hydrocarbons (PAH), fibrous components and meso- and macropores according to X-ray emission spectroscopy >99 mol% and a particle size determined by electron microscopy in the range from 100 nm to 1000 nm, for use in medicine.

Description

field of invention

The present invention relates to mechanochemically pretreated, heavy metal-free activated carbon particles A for use in medicine.

Furthermore, the present invention relates to topical medicaments for use in medicine, containing mechanochemically pretreated, heavy metal-free activated carbon particles A

In addition, the present invention relates to a process for the production of heavy-metal-free topical medicinal products containing mechanochemically pretreated, heavy-metal-free activated carbon particles A.

Last but not least, the present invention relates to the coatings and coating materials on and/or in release materials that are evident in the form of powders, solids, gels, creams, ointments, lotions, drops, sprays, metered dose aerosols, gargling solutions, lozenges, enemas, enemas, foams, release materials , sponges, textile fabrics, face masks, gauze and plasters, as well as topical medicinal products free of heavy metals prepared on and/or in roll-on pens, dispensers and medical devices, containing mechanochemically pretreated, heavy metal-free activated carbon particles A.

State of the art

In medicine, topical drugs are all those drugs that are not taken or injected, but applied locally. Since the active substance is brought directly to the site of action with topical application, the dose can often be reduced as far as possible and the risk of side effects thus reduced. All organs lying on the surface, i.e. the skin and the mucous membranes of the respiratory tract, the digestive tract and the outer eye, are accessible to local treatment or care. But an injection into a joint is also a topical (local, intra-articular) treatment.

Topical drugs play a particularly important role in dermatology, as well as in ophthalmology (ophthalmology) and urology.

• • an der Haut: Salben, Cremes und Lotionen
• • an der Nase: Nasentropfen, -sprays und -salben
• • an der Mundschleimhaut: Gurgellösungen und Lutschtabletten
• • an den Atemwegen: Dosieraerosole, Vernebelung mit UV-Licht und Pulverinhalatoren
• • am Darm: Einläufe und Klistiere
• • an den Bindehäuten der Augen: Tropfen, Salben und Sprays

zur Anwendungcome in particular

• • on the skin: ointments, creams and lotions
• • on the nose: nasal drops, sprays and ointments
• • on the oral mucosa: gargling solutions and lozenges
• • on the respiratory tract: metered dose aerosols, fogging with UV light and dry powder inhalers
• • on the intestines: enemas and enemas
• • on the conjunctiva of the eyes: drops, ointments and sprays

for application

Antibiotics can also be used topically, for example for bacterial skin infections. Sulfonamides in particular are used here.

The drugs are used, among other things, to combat unpleasantly smelling, painful, itchy, caustic, unaesthetic and inflammatory external, i. H. topical, diseases. They are also used for the topical treatment of injuries and burns.

From the German utility model DE 20 2014 010 286 U1 cosmetic cleaning products for the skin and/or hair are known which contain surfactants, preferably anionic and amphoteric surfactants, activated carbon in the form of activated carbon particles with a particle size of 0.5 to 60 μm, pearlescent agents selected from the group of ethylene glycol monostearates, polyethylene glycol distearates and Glycol distearate and at least one structurant from the group of acrylate copolymers and the alkoxylated Ver thicker included. CI 77266 Carbon Black is used as activated carbon. No further information is given about the activated carbon. The use as a medicinal product is also not described.

• - zur Adsorption und/oder Zersetzung von Chemotherapeutika, die über die Haut abgeschieden wurden,
• - als Saunapaste Entschlackung des Körpers,
• - als Peelingpaste,
• - als fettfreie Feuchtigkeits- und Reinigungscreme,
• - als Schutzprodukt für das Pflegepersonal, welches mit Chemotherapeutika in Berührung kommt,
• - als Duschgel
• - als Salbe zur begleitenden Behandlung von Calcinosis cutis und
• - als Lotion zur Pflege der Kopfhaut und Haarwurzeln

verwendet werden. Außerdem geht aus den Versuchsberichten in der Akte hervor, dass die topischen Medizinprodukte den heftigen Juckreiz nach dem Kontakt der menschlichen Haut mit Eichenprozessionsspinnern und die schmerzhaften Schwellungen von Gelenken, die von Arthrose befallen sind, rasch lindern.From the German patent application DE 10 2017 010 930 A1 and the corresponding international patent application WO 2019/101357 A1 topical medicinal products are known which contain at least one type of carbon particles with an average particle size d ₅₀ =650±200 nm. These topical medicinal products can

• - for the adsorption and/or decomposition of chemotherapeutic agents excreted through the skin,
• - as a sauna paste for detoxification of the body,
• - as a peeling paste,
• - as a fat-free moisturizing and cleansing cream,
• - as a protective product for nursing staff who come into contact with chemotherapeutic agents,
• - as a shower gel
• - as an ointment for the concomitant treatment of calcinosis cutis and
• - as a lotion for the care of the scalp and hair roots

be used. In addition, the test reports in the file show that the topical medicinal products quickly relieve the intense itching after contact of human skin with oak processionary moths and the painful swelling of joints affected by osteoarthritis.

The known topical medical products contain the activated carbon particles in an amount of 0.01% by weight to 10% by weight, based on the respective total amount of a topical preparation.

In order to increase the effect of the topical drugs and thereby decrease the amount of drugs to be applied, it would be desirable to make the activated carbon particle content of the topical drugs particularly high. However, the known topical medical products that contain more than 10% by weight of activated carbon particles tend to separate, which necessitates larger amounts and stabilizers. As a result, however, the performance profile of properties is changed in an unfavorable manner in an unpredictable manner.

Object of the present invention

The object of the present invention was to provide topical medicaments for use in medicine.

The topical medicaments are intended to be conspicuously in the form of powders, solids, gels, creams, ointments, lotions, drops, sprays, metered dose inhalers, gargles, lozenges, enemas, enemas, foams, release materials coatings and coating materials on and/or in release materials, sponges, textile fabrics, face masks, gauze and plasters as well as on and/or in roll-on pens, dispensers and medical devices.

The topical medicaments should be particularly excellent for the therapeutic treatment of inflammatory diseases and infections, wounds, burns, chemical burns, lesions, itching, burning, intertrigo, infections and discolorations and pain (i) in and on the skin, in and on mucous membranes, in particular in and on mucous membranes in the mouth, and in and on the genitals, (ii) in the intestines, (iii) in and on the eyes, ears, mouth, lips, fingernails, toenails, calluses, warts and scars, (iv) to heal the consequences excretion of noxae, drugs, toxins, medicines, acids and bases through the skin and (vi) for preventive protection of humans and animals.

Furthermore, the topical medicaments should not harm the environment and, in particular, should not accumulate in organisms in the marine food chain.

In addition, it is an object of the present invention to find a process for the production of the topical medicaments.

Solution according to the invention

Accordingly, the mechanochemically pretreated, heavy metal-free activated carbon particles A were found for use in medicine, in particular human and veterinary medicine.

Furthermore, the topical medicaments for use in medicine according to independent claim 2 have been found. Advantageous embodiments of the topical medicaments are the subject matter of dependent claims 3 to 16.

In addition, the method of independent claim 17 for the production of the topical medicaments according to one of claims 2 to 16 has been found. An advantageous embodiment of the method is the subject of dependent claim 18.

Last but not least, the obvious arrangements of the topical medicinal products according to the secondary claim 18 were found.

Advantages of the Invention

In view of the prior art, it is surprising and unforeseeable for the person skilled in the art that the object on which the present invention is based, by means of the mechanochemically pretreated, heavy metal-free activated carbon particles A, the topical medicaments according to the invention, the method according to the invention for the production and their inventive obvious preparation is solved.

In particular, it is surprising that the topical drugs are obviously in the form of powders, solids, gels, creams, ointments, lotions, drops, sprays, metered dose aerosols, gargling solutions, lozenges, enemas, enemas, foams, release materials, coatings and coating materials on and/or in release materials, sponges, textile fabrics, tampons, face masks, gauze and plasters as well as on and/or in roll-on pens, dispensers and medical devices.

The topical medicinal products for use in human and veterinary medicine are particularly suitable for the therapeutic treatment of inflammatory diseases and infections, wounds, burns, chemical burns, lesions, itching, burning, intertrigo, infections and discoloration and pain (i) in and on the skin, in and on mucous membranes, especially in and on mucous membranes in the mouth, and in and on genitals, (ii) in the gut, (iii) in and on eyes, ears, mouth, lips, fingernails, toenails, calluses, warts and scars , (iv) to heal the consequences of excretion of noxae, drugs, toxins, medicines, acids and bases through the skin and (vi) for preventive protection of humans and animals.

Furthermore, the topical drugs do not harm the environment and, in particular, they do not accumulate in organisms in the marine food chain.

Furthermore, the topical medicaments according to the invention can be produced in a simple and very well reproducible manner using the method according to the invention.

It is particularly surprising that the production of the topical medicinal products according to the invention largely or exclusively uses renewable, compostable, toxicologically harmless, biodegradable and/or recyclable raw materials, so that the production and use of the topical medicinal products according to the invention are particularly environmentally friendly and act as a carbon dioxide sink.

The binding and/or absorption of pollutants by the skin by the topical medicaments according to the invention is particularly surprising. In particular, drugs secreted through the skin and mucous membranes, in particular cytostatics, are prevented from being reabsorbed and rendered harmless. Thus, the topical medicaments according to the invention are tolerable for allergy sufferers and/or for all skin types. In addition, they can be made bacteriostatic, antiviral, fungicidal or fungistatic and nematicidal in a simple manner.

All these advantageous effects of the topical drugs according to the invention are enhanced by their excellent penetration depth into the skin and into the mucous membranes. They can therefore also serve as carriers for other drugs.

Furthermore, it is surprising that the medicaments according to the invention are free from heavy metals, polycyclic aromatic compounds (PAH) and persistent pollutants (POP).

Detailed Description of the Invention

The medicaments according to the invention contain, under at least one inert gas, activated carbon particles A with a carbon content >99 mol %, preferably >, which have been mechanochemically pretreated and, according to X-ray emission spectroscopy, are free of heavy metals and of persistent organic pollutants (POP), polycyclic aromatic hydrocarbons (PAH), fibrous components and meso- and macropores 99.2 mol%, a particle size determined by electron microscopy in the range from 100 nm to 1000 nm, preferably 200 nm to 900 nm, preferably 300 nm to 800 nm and in particular 400 to 700 nm.

The at least one inert gas is preferably selected from the group consisting of nitrogen, helium, neon, argon and xenon. The inert gases, in particular nitrogen, can also be present in solid and/or liquid form. Liquid nitrogen is particularly advantageous because its low surface tension finely disperses the ground material particularly quickly. The inert gases can also be present as solids, which has the advantage that they act as additional grinding media.

The absence of meso- and macropores is demonstrated by means of electron micrographs.

The electron micrographs also show that the activated carbon particles A according to the invention all have a granular structure and no fibrous structures like those in the publication by DV Onishchenko, "Mechanochemical Treatment of Amorphous Carbon from Brown Sphagnum Moss for the Preparation of Carbon Nanotubes" in Surface Engineering and Applied Electrochemistry, 2013, Vol. 49, No. 6, pages 445-449.

In the context of the present invention, the term "heavy metals" includes strontium, barium, scandium, yttrium, lanthanum and the lanthanides, the actinides, titanium, zirconium, hafnium, chromium, molybdenum, tungsten, manganese, technetium, rhenium, iron, ruthenium, osmium, nickel , palladium, platinum, copper, silver, gold, zinc, cadmium, mercury, gallium, indium, thallium germanium, tin, lead, arsenic, antimony, bismuth, selenium and tellurium and the compounds of these metals.

In the context of the present invention, the property “free of heavy metals” means that the concentrations of the respective heavy metals are below the maximum limits permitted by food law and medical law.

Acenaphthylen

Acenaphthen

Fluoren

Phenanthren

Anthracen

Fluoranthen

Pyren

Benzo[a]anthracen

Chrysen

Benzo[b]fluoranthen

Benzo[k]fluoranthen

Benzo[a]pyren

Dibenzo[a,h]anthracen

Indeno[1,2,3-cd]pyren

Benzol[ghi]perylen

Polycyclic aromatic hydrocarbons PAH are in particular The 16 "EPA-PAH" naphthalene

acenaphthylene

acenaphthene

fluorene

phenanthrene

anthracene

fluoranthene

pyrene

Benzo[a]anthracene

chrysen

benzo[b]fluoranthene

benzo[k]fluoranthene

benzo[a]pyrene

Dibenzo[a,h]anthracene

indeno[1,2,3-cd]pyrene

benzene[ghi]perylene

The persistent organic pollutants (POP) are mainly halogenated organic compounds that accumulate in the food chain. All substances included in the Stockholm Convention belong to this group. The so-called dirty dozen consists only of organochlorine compounds. Of particular importance are the organochlorine pesticides such as DDT or endrin. In addition, there are brominated flame retardants and polyfluorinated compounds such as perfluorooctane sulfonates (PFOS), which are used as surface-active substances in textiles.

PAH and POP concentrations are generally measured using GC-MS coupling. The activated carbon particles A according to the invention are considered to be free of PAHs and POPs if they cannot be detected using this method.

The production of the activated carbon particles to be used according to the invention is described in detail in the German patent application filed at the same time with the internal file number LUT 2103-1 and the title: “Mechanochemically pretreated, heavy metal-free activated carbon particles A”.

The amounts of activated carbon particles A used in the topical medicaments according to the invention can vary very widely and depend primarily on their intended use. The amounts used are preferably from 0.1% by weight to 50% by weight, preferably from 0.5% by weight to 40% by weight, particularly preferably from 1.0% by weight to 30% by weight. and in particular 2% by weight to 20% by weight in each case based on the total amount of a given topical medicament according to the invention. The high dosages can be used for special applications. Have the topical drugs in question then the form of viscous pastes or slurries with a content of activated carbon particles A of up to 50% by weight.

Particularly advantageous topical medicaments according to the invention contain particles B with an average particle size d ₅₀ equal to 10 nm to <1000 μm, preferably 20 nm to 1000 nm, preferably 30 nm to 800 nm and in particular 40 nm to 600 nm of at least one, in particular one, type of nanocrystalline and/or microcrystalline natural wax and/or semi-synthetic wax based on natural wax and/or biodegradable microplastics.

The term wax is a phenomenological term for a range of naturally or artificially or synthetically obtained substances, which usually have the following properties: kneadable at 20 °C, solid to brittle-hard, coarse to fine-crystalline, translucent to opaque, non-glassy, melting above 40 °C without decomposition, but relatively low-viscosity just above the melting point and generally or advantageously not stringy, have a highly temperature-dependent consistency and solubility and can be polished under slight pressure. If more than one of the properties listed above is not met, this substance is not a wax according to the DGF (German Society for Fat Science) (cf. DGF standard method M-I 1 (75)). Waxes differ from similar synthetic or natural products such as resins, plastic masses, metal soaps, etc. mainly in that they are generally between 50 °C and 90 °C, in exceptional cases up to around 200 °C, in the molten, low-viscosity state and are practically free of ash-forming compounds. Waxes form pastes or gels and usually burn with a sooty flame.

Further details on the concept of waxes can be found in Römpp Chemielexikon, 10th edition, volume 6, 19199, Georg Thieme Verlag Stuttgart/New York, page 09/04/2006, keyword: "Waxes" and the literature referred to there, in particular Cos. Toil. 101,49 (1986 as well as DGF unit methods, department M waxes and wax products, 7th supplement, 05/1999, Stuttgart.

According to the invention, it is preferred if a wax B is used which contains polar functional groups, in particular groups that contain heteroatoms from the group consisting of oxygen, nitrogen and/or sulfur, preferably oxygen, particularly preferably hydroxyl groups, polyether groups, in particular polyethylene oxide groups, and/or or carboxyl groups.

Examples of suitable natural waxes are vegetable waxes such as xanthan gum, candelilla wax, carnauba wax, Japan wax, esparto grass wax, cork wax, guaruma wax, rice germ oil wax, sugar cane wax, ouricury wax, montan wax, absolute flower waxes, Cuban palm wax, cotton wax, flax wax, peat wax, rose wax, jasmine wax, peetha wax, myrtle wax and waxy fig wax.

Examples of suitable natural waxes are animal waxes such as spermaceti, wool wax, shellac, china wax, beeswax and preen gland wax.

Examples of suitable natural waxes are mineral waxes such as ceresin and ozokerite.

Examples of suitable modified natural waxes are hard waxes, montan ester waxes, sasol waxes, hydrogenated jojoba waxes, wool wax alcohols (Eucerit), and modified beeswax (Cerabellina).

Beeswax, cerabellina and absolute flower waxes are particularly preferably used.

The wax particles B are preferably made from natural and semi-synthetic waxes using the GAS (Gas Antisolvent Recrystallization) method, the PCA (Precipitation with a Compressed Fluid Antisolvent) method, the PGSS (Particles from Gas Saturated Solutions) method or the RESS method (Rapid Expansion of Supercritical Solutions) (see, for example, the American patent applications US2012/0258150A1 and US 2013/0259913 A1 ).

Instead of or in addition to the wax particles B, the topical medicaments according to the invention can contain biodegradable and non-degradable microplastics or microbeads, which is however less preferred according to the invention. If non-biodegradable microplastics are used, their quantities should be kept as low as possible.

Suitable biodegradable microbeads B are, for example, from the American patent application 2014/0026916 A1 known. They have an average particle size d ₅₀ <400 µm and consist of polyhydroxyalkanoates. Polyhydroxyalkanoates (PHA) or polyhydroxyfatty acids (PHF) are naturally occurring water-insoluble and linear polyesters produced by many bacteria as carbon and energy reservoirs. In nature, they are made by fermenting sugar or fats. These biopolymers are biodegradable and are used to produce bioplastics. They have the advantage that they sink to the bottom in the water and are biodegradable.

Other suitable biodegradable microbeads B are, for example, from the American patent application US 2010/0278882 A1 known. They consist of cross-linked proteins, such as silk proteins, and have an average particle size d ₅₀ of 0.1 μm to 100 μm.

Other suitable biodegradable microbeads B are also from the European patent application EP 0 563 876 A2 known. They are made by cross-linking natural proteins such as gelatin, albumin and casein using glyceraldehyde as a cross-linking agent.

The average particle size d ₅₀ of the wax particles B and/or the biodegradable microbeads B can vary widely and can thus be perfectly adapted to the requirements of the individual case. The average particle size d ₅₀ is preferably between 1 μm and <1000 μm, preferably 10 μm to 700 μm, particularly preferably 50 μm to 500 μm and in particular 100 μm to 300 μm.

The wax particles B and/or the biodegradable microbeads B can be protected from aggregation or agglomeration by protective colloids. Protective colloids are mostly water-soluble, preferably biodegradable, polymers such as partially hydrolyzed polyvinyl acetate, polyvinyl alcohol, polyvinylpyrrolidone, cellulose ethers (tylose) such as methyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, starch, proteins, alginates, pectins and gelatin.

The content of wax particles and/or biodegradable microbeads B in the topical medicaments according to the invention can vary widely and can thus be excellently adapted to the respective intended use. A given topical preparation according to the invention preferably contains, based on its total amount, 0.1% to 50% by weight, 0.5 to 45% by weight and in particular 1% to 40% by weight of wax particles B.

Further advantageous topical medicaments according to the invention contain particles C with an average particle size d ₅₀ of 10 nm to <1000 nm, preferably 300 nm to 900 nm, preferably 650±200 nm and in particular 650±100 nm. They contain at least one type and/or consist of at least one type of nanocrystalline, nanofibrillar, microcrystalline and/or microfibrillar polysaccharides. In particular, cellulose nanofibers (CNF), microfibrillar cellulose (MFC), microcrystalline cellulose (MCC), nanofibrillar polysaccharides (NFP), nanocrystalline cellulose (CNC), bacterial nanocellulose (BNC) and waste from paper mash from paper manufacture and fibers and particles from used textiles are used.

The content of particles C in the topical medicaments according to the invention can vary widely and can thus be excellently adapted to the respective intended use. A given topical preparation according to the invention preferably contains, based on its total amount, 0.01% by weight to 10% by weight, preferably 0.02% by weight to 9% by weight and in particular 0.03 to 8% by weight. -%.

In addition, the topical drugs according to the invention can contain at least one ingredient D commonly used for topical drugs, selected from the group consisting of water, alcohols, phyllosilicates, ground clays, Bolus Americus clays, healing clays, pharmacologically approved salts, nut shells, willow barks, Lapacho healing barks, silica , pumice stones, geopolymers, amber, precious stones, trace elements and neutral inorganic salts, beta-glucans, glutathione, albumin, xylan, phytates, complexing agents, antioxidants, radical scavengers, menthol, caffeine, theine, papain, esculine semihydrate, carotenoids, lecithins, abscisic acid, cyanidin , guanidine, urea, thiourea, fillers, solvents, humectants, solubilizers, nonionic wetting agents, buffers, thickeners, binders, coating agents, disintegrants, disintegrants, lubricants, lubricants, mold release agents, flow regulators In, antioxidants, preservatives, sweeteners, flavor enhancers, absorption accelerators, alkalizing agents, acidifiers, neutralizing agents, foam inhibitors and defoamers, dyes, color pigments, oxidizing agents, reducing agents, stabilizers, propellants, opacifiers, pearlescent substances, denaturants, plasticizers, minerals, vitamins, micelles, superabsorbents, moisturizing sub punch, oils, fragrances, flavorings, perfumes, moisturizers, moisturizers, active ingredients for skin care, deodorizing active ingredients, film formers, gel formers, tanning agents, tanning agents, tanning extracts, bitter substances, plant extracts, honey, colostrum, cytostatics, antibodies, immunoglobulins, essential and non-essential Amino acids and fats, hyaluronic acid, aloe vera gel, alkylene glycols, polyalkylene ether glycols, proteins, peptides, carbohydrates, lipids, nucleic acids, nucleic acid fragments, antiviral compounds, disinfectants, antibiotics, cell differentiation agents, analgesics, anesthetics, anesthetics, contrast media, enzymes, cytokines, antihistamines, immunomodulators , hemostatic agents, hormones, angiogenic and antiangiogenic agents, neurotransmitters, therapeutic oligonucleotides, viral particles, growth factors, retinoids, cell adhesion factors, extracellular matrix glycoproteins, osteogenic en factors, antibodies, antigens, steroids, analgesics, potassium sulfate, royal jelly, propolis, encapsulated fragrances, nutrients hexahydroxycyclohexanehexaphosphoric acid ester salt nanoparticles, especially salts of phytic acid, and surfactants, contained in effective amounts.

Examples of suitable ingredients D are, in particular, phyllosilicates, which are preferably present as nanoparticles and/or microparticles with an average particle size d ₅₀ of 1 nm to <1000 μm, preferably 10 nm to 900 μm, preferably 300 nm to 1000 nm, particularly preferably 650±200 nm, very particularly preferably 650 ± 150 nm and in particular 650 ± 100 nm

• - Inselsilikate
• - Gruppensilikate
• - Ringsilikate
• - Ketten- und Bandsilikate
• - Übergangsstrukturen zwischen Ketten- und Schichtsilikaten
• - Schichtsilikate
• - Gerüstsilikate

The elementary composition and the structure of the layered silicate micro- and/or nanoparticles can also vary widely. For example, the classification of silicates into the following structures is known:

• - Island silicates
• - group silicates
• - ring silicates
• - chain and ribbon silicates
• - Transitional structures between chain and sheet silicates
• - layered silicates
• - tectosilicates

Layered silicates are silicates whose silicate cations consist of layers of corner-sharing SiO ₄ tetrahedra. These layers and/or double layers are not further linked to one another. The technically important clay minerals that are widespread in sedimentary rock are also phyllosilicates. The layered structure of these minerals determines the shape and properties of the crystals. They are mostly tabular to laminar with good to perfect cleavage parallel to the layers. The number of rings that make up the silicate layers often determines the symmetry and shape of the crystals. Water molecules, large cations and/or lipids can be stored between the layers.

1. a) vgl. Mineralienatlas, Mineralklasse VIII/H - Schichtsilikate (Phyllosilikate), Strunz 8 Systematik

Examples of suitable layered silicates free of heavy metals are given in Table 1 below. The list is exemplary and not exhaustive. Table 1: Molecular formulas of suitable heavy-metal-free phyllosilicates ^a) Type molecular formula martinite (Na,Ca) ₁₁ Ca ₄ (Si,S,B) ₁₄ B ₂ O ₄₀ F ₂ 4(H ₂ O) Apophyllite-(NaF) NaCa ₄ Si ₈ O ₂₀ F 8H ₂ O Apophyllite-(KF) (K,Na)Ca ₄ Si ₈ O ₂₀ (F,OH) 8H ₂ O Apophyllite-(KOH) KCa ₄ Si _s O ₂₀ (OH,F) 8H ₂ O Natrosilite _{Na2Si2O5 _ _} kanemite _{NaSi2O5.3H2O _ _} revdit Na ₁₆ Si ₁₆ O ₂₇ (OH) ₂₆ .28H ₂ O Latiumit (Ca,K) ₄ (Si,Al) ₅ O ₁₁ (SO ₄ ,CO ₃ ) Tuscanite K(Ca,Na) ₆ (Si,Al) ₁₀ O ₂₂ (SO ₄ ,CO ₃ ,(OH) ₂ ) H ₂ O carletonite KNa ₄ Ca ₄ Si ₈ O ₁₈ (CO ₃ ) ₄ (OH,F) H ₂ O pyrophyllite _{Al2Si4O10 (} OH _{) 2} talc _{Mg3Si4O10 ( OH} ) ₂ paragonite NaAl ₂ (Si ₃ Al)O ₁₀ (OH) ₂ boromuscovite KAl ₂ (Si ₃ B)O ₁₀ (OH,F) ₂ Muscovite KAl ₂ (Si ₃ Al)O ₁₀ (OH,F) ₂ Tobelith (NH ₄ ,K)Al ₂ (Si ₃ AI)Oio(OH) ₂ Nanpingit CsAl ₂ (Si,Al) ₄ O ₁₀ (OH,F) ₂ polylithionite KLi ₂ AlSi ₄ O ₁₀ (F,OH) ₂ tainiolite _{KLiMg2Si4O10F2 _ _ _} shirokshinite KNaMg ₂ [F ₂ |Si ₄ O ₁₀ ] trilithionite KLi ₁₅ Al _1.5 [F ₂ |AlSi ₃ O ₁₀ ] Aspidolite-1M _NaMg3 (A) _Si3 ) _O10 (OH) ₂ fluorophlogopite _{KMg3 ( AlSi3} ) _O10F2 phlogopite KMg ₃ (Si ₃ Al)O ₁₀ (F,OH) ₂ Ephesite _NaLiAl2 ( _{Al2Si2 ) O10} (OH) ₂ price work kit _{NaMg2Al3Si2O10 ( OH ) 2} eastonite KMg ₂ Al[(OH) ₂ |Al ₂ Si ₂ O ₁₀ ] margarita CaAl ₂ (Al ₂ Si ₂ )O ₁₀ (OH) ₂ clintonite Ca(Mg,Al) ₃ (Al ₃ Si)O ₁₀ (OH) ₂ illiterate (K,H ₃ O)Al ₂ (Si ₃ Al)O ₁₀ (H ₂ O,OH) ₂ agrelite _{NaCa2Si4O10F _ _} glagolevite NaMg ₆ [(OH,O) ₈ |AlSi ₃ O ₁₀ ] H ₂ O Lunijianlait Li _0.7 Al _6.2 (Si ₇ Al ₂₀ )(OH,O) ₁₀ saliotite Na _0.5 Li _0.5 Al ₃ [(OH) ₅ | AlSi ₃ O ₁₀ ] coolness Na _0.35 Mg ₈ Al(AlSi ₇ )O ₂₀ (OH) ₁₀ Aliettit Ca _0.2 Mg ₆ (Si,Al) ₈ O ₂₀ (OH) ₄ 4H ₂ O rectorite (Na,Ca)Al ₄ (Si,Al) ₈ O ₂₀ (OH) ₄ .2H ₂ O Tarasovite (Na,K,H ₃ O,Ca) ₂ Al ₄ [(OH) ₂ |(Si,Al) ₄ O ₁₀ ] ₂ H ₂ O tosudit Na _0.5 (Al,Mg) ₆ (Si,Al) ₈ O ₁₈ (OH) ₁₂ 5H ₂ O montmorillonite (Na,Ca) _0.3 (Al,Mg) ₂ Si ₄ O ₁₀ (OH) ₂ nH ₂ O beidellite (Na,Ca _0.5 ) _0.3 Al ₂ (Si,Al) ₄ O ₁₀ (OH) ₂ .4H ₂ O Swinefordite (Ca,Na) _0.3 (Al,Li,Mg) ₂ (Si,Al) ₄ O ₁₀ (OH,F) ₂ 2H ₂ O hectorite Na _0.3 (Mg,Li) ₃ Si ₄ O ₁₀ (F,OH) ₂ spadait MgSiO ₂ (OH) ₂ H ₂ O Stevensite (Ca| ₂ ) _0.3 Mg ₃ Si ₄ O ₁₀ (OH) ₂ Donbasit Al _2.3 [(OH) ₈ |AlSi ₃ O ₁₀ ] sudoit _{Mg2Al3 ( Si3Al} ) _O10 (OH) ₈ Cookeit LiAl ₄ (Si ₃ Al)O ₁₀ (OH) ₈ Borocooness Li _1-1.5 Al _4-3.5 [(OH,F) ₈ |(B,Al)Si ₃ O ₁₀ ] manandonite _Li2Al4 [( _Si2AlB ) _O10 ] ₍ OH) ₈ kaolinite _{Al2Si2O5 (} OH _{) 4} dickit _{Al2Si2O5 (} OH _{) 4} Halloysite-7Å _{Al2Si2O5 (} OH _{) 4} allophane _{Al2 O3} ( _SiO2 ) _1.3-2 ·( _H2 O) _2.5-3 imogolite _{Al2SiO3 (} OH) ₄ chrysotile _{Mg3Si2O5 ( OH} ) ₄ clinochrysotile _{Mg3Si2O5 ( OH} ) ₄ orthochrysotile _{Mg3Si2O5 ( OH} ) ₄ parachrysotile _{Mg3Si2O5 ( OH} ) ₄ lizardite _{Mg3Si2O5 ( OH} ) ₄ amesite _Mg2Al (SiAl) _O5 (OH) ₄ palygorskite (Mg,Al) ₂ Si ₄ O ₁₀ (OH) 4H ₂ O loughlinite Na ₂ Mg ₃ Si ₆ O ₁₆ 8H ₂ O caliber site (K,Na) ₅ Fe ₇ ³⁺ [(OH) ₃ | Si ₁₀ O ₂₅ ] ₂ .12H ₂ O minehillite (K,Na) _2-3 Ca ₂₈ (Zn ₄ Al ₄ Si ₄₀ )O ₁₁₂ (OH) ₁₆ fedorite (Na,K) _2-3 (Ca,Na) ₇ [Si ₄ O ₈ (F,Cl,OH)2|(Si ₄ O ₁₀ ) ₃ ] 3.5H ₂ O reyerite (Na,K) ₄ Ca ₁₄ Si ₂₂ Al ₂ O ₅₈ (OH) ₈ 6H ₂ O gyrolite NaCa ₁₆ Si ₂₃ AlO ₆₀ (OH) ₈ .14H ₂ O zeophyllite Ca ₄ Si ₃ O ₈ (OH,F) ₄ .2H ₂ O mountainite KNa ₂ Ca ₂ [Si ₈ O ₁₉ (OH)] 6H ₂ O Rhodesite _{KHCa2Si8O19.5H2O _ _ _} Delhayelith K ₇ Na ₃ Ca ₅ Al ₂ Si ₁₄ O ₃₈ F ₄ Cl ₂ hydrodel hayelite KCa ₂ AlSi ₇ O ₁₇ (OH) ₂ .6H ₂ O Tienshanite (Na,K) _9-10 (Ca,Y) ₂ Ba ₆ (Mn ²⁺ ,Fe ²⁺ ,Ti ⁴⁺ ,Zn) ₆ (Ti,Nb) [(O,F,OH) ₁₁ |B ₂ O ₄ | _{Si6O15 ] 6} silhydrite _{Si3O6.H2O _ _} magadiite _{Na2Si14O29.11H2O _ _ _} Stratlingit Ca ₂ Al[(OH) ₆ AlSiO ₂ (OH) ₄ ] 2.5 H ₂ O vertumnit Ca ₄ Al ₄ Si ₄ O ₆ (OH) ₂₄ .3H ₂ O

1. a) cf. Mineralienatlas, mineral class VIII/H - sheet silicates (phyllosilicates), Strunz 8 systematics

Heavy metal-free bentonite from the group of montmorillonites ((Na,Ca) _0.3 (Al,Mg) ₂ Si ₄ O ₁₀ (OH) ₂ .H ₂ O) is very particularly preferred. Bentonite is a mixture of different clay minerals and contains montmorillonite as the most important component. Sodium bentonite, for example, absorbs water, it can absorb many times its own dry weight. Calcium bentonite can also absorb fats and/or oils.

The layered silicate micro- and/or nanoparticles described above are functionalized, non-functionalized, aggregated, non-aggregated, agglomerated, non-agglomerated, supported and/or unsupported. For example, they can be functionalized, agglomerated, and supported. However, they can also be non-functionalized and aggregated.

• • Lactose, Cellulose, Stärken, Saccharose (Tabletten)
• • Paraffin (Salben); Hartfett (Zäpfchen)
• • Polyethylenglykole (Macrogole, PEG); Polyethylenoxide (PEO) (Tabletten, Salben, Cremes);
• • Lösungsmittel und/oder Befeuchtungsmittel: VC-Wasser, Ethanol, Isopropanol (Granulierung, Filmsprühung)
• • Emulgatoren: Cetylstearylalkohol, Gylcerolmonostearat, Lecithin, Fettsäureester des Sorbitans, des Polyoxyethylensorbitans (Polysorbate), des Polyoxyethylens, Polyoxyethylenfettalkoholether (Emulsionen, Cremes), Methylglucose, Sesquistearate, Stearinsäure und deren Derivate, Emulgatoren auf Acrylat-Basis wie z.B. Acrylates/C10-330 Alkyl Acrylate Crosspolymer
• • Lösungsvermittler und/oder Netzmittel: Polyethylenglykole (PEG, Macrogole), Polyethylenoxide (PEO, PolyOx), Polysorbate (Lösungen, Suspensionen)
• • Puffer: Dikaliumhydrogenphosphat Natriumdihydrogenphosphat, Natriumhydrogencarbonat, Calciumhydrogenphosphat, Trometamol (Lösungen, Cremes)
• • Verdickungs- und Bindemittel: Stärken, Guaran, Xanthangummi, Alginat, Carrageen, Pektin, Traganth, Polyacrylsäuren, Polyvinylpyrrolidon (Granulate, Tabletten); hochdisperses Siliciumdioxid, substituierte Celluloseether (Methylcellulose, Ethylcellulose, Hydroxypropylcellulose, Hydroxypropylmethylcellulose, Carboxymethylcellulose) (Tabletten, Gele, viskose Lösungen), Butyrospermum Parkii Butter, MAGNESIUM SULFATE
• • Umhüllungsmittel: Saccharose (Zuckerdragierung); Gelatine (Kapseln); Gelatinepolysuccinat („Weichkapseln“), Polyacrylate, Ethylcellulose, Methylcellulose (Filmcoating: Filmkapseln, Filmtabletten, Pellets)
• • Zerfallsbeschleuniger und/oder Sprengmittel: Stärken (Tabletten, Tabs); Croscarmellose (Tabletten, Kapseln, Granulate); Natriumhydrogencarbonat in Kombination mit Citronensäure (Brausetabletten)
• • Gleit- und Schmiermittel und/oder Formentrennmittel: Polyethylenglykole (PEG, Macrogole), Polyethylenoxide (PEO), Talkum, Magnesiumstearat (Tablettierung)
• • Fließregulierungsmittel: Hochdisperses Siliciumdioxid (Pulver, Granulate)
• • Antioxidantien: Butylhydroxytoluol, all-rac-α-Tocopherol
• • Konservierungsstoffe: PHB-Ester, Benzalkoniumchlorid, Benzylalkohol, Thiomersal
• • Süßungsmittel, Geschmackkorrigientien: Saccharose, Sorbit, Süßstoffe wie etwa Saccharin-Natrium und Cyclamat
• • Aromen
• • Resorptionsbeschleuniger: Dimethylsulfoxid (in topischen Arzneimitteln)

Examples of other suitable, preferably halogen-free, ingredients D are:

• • Lactose, cellulose, starches, sucrose (tablets)
• • paraffin (ointments); hard fat (suppositories)
• • polyethylene glycols (macrogols, PEG); Polyethylene oxides (PEO) (tablets, ointments, creams);
• • Solvents and/or wetting agents: VC water, ethanol, isopropanol (granulation, film spraying)
• • Emulsifiers: cetylstearyl alcohol, glycerol monostearate, lecithin, fatty acid esters of sorbitan, polyoxyethylene sorbitan (polysorbate), polyoxyethylene, polyoxyethylene fatty alcohol ether (emulsions, creams), methyl glucose, sesquistearates, stearic acid and its derivatives, emulsifiers based on acrylate such as acrylates/C10-330 Alkyl Acrylate Crosspolymer
• • Solubilizers and/or wetting agents: polyethylene glycols (PEG, macrogols), polyethylene oxides (PEO, PolyOx), polysorbates (solutions, suspensions)
• • Buffers: dipotassium hydrogen phosphate, sodium dihydrogen phosphate, sodium hydrogen carbonate, calcium hydrogen phosphate, trometamol (solutions, creams)
• • Thickening and binding agents: starches, guar gum, xanthan gum, alginate, carrageenan, pectin, tragacanth, polyacrylic acids, polyvinylpyrrolidone (granules, tablets); colloidal silica, substituted cellulose ethers (methylcellulose, ethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose) (tablets, gels, viscous solutions), butyrospermum parkii butter, MAGNESIUM SULFATE
• • Coating agent: sucrose (sugar coating); gelatin (capsules); Gelatin polysuccinate ("soft capsules"), polyacrylates, ethyl cellulose, methyl cellulose (film coating: film capsules, film tablets, pellets)
• • Disintegrants and/or disintegrants: starches (tablets, tabs); croscarmellose (tablets, capsules, granules); Sodium bicarbonate in combination with citric acid (effervescent tablets)
• • Lubricants and/or mold release agents: polyethylene glycols (PEG, macrogols), polyethylene oxides (PEO), talc, magnesium stearate (tablets)
• • Flow regulator: highly dispersed silicon dioxide (powder, granules)
• • Antioxidants: butylated hydroxytoluene, all-rac-α-tocopherol
• • Preservatives: PHB esters, benzalkonium chloride, benzyl alcohol, thiomersal
• • Sweeteners, flavorings: sucrose, sorbitol, sweeteners such as sodium saccharin and cyclamate
• • Flavors
• • Absorption accelerator: dimethyl sulfoxide (in topical drugs)

Other tools include

• • ACETIC ACID Essigsäure
• • AMINOMETHYL PROPANOL 2-Amino-2-methylpropanol
• • AMMONIA Ammoniak
• • AMMONIUM BICARBONATE Ammoniumbicarbonat, Ammoniumhydrogencarbonat
• • AMMONIUM CARBONATE Ammoniumcarbonat
• • CITRIC ACID Zitronensäure, Citronensäure
• • DISODIUM PHOSPHATE Dinatriumhydrogenphosphat
• • DISODIUM PYROPHOSPHATE Dinatriumdihydrogenpyrophosphat
• • ETHANOLAMINE Ethanolamin, 2-Aminoethanol
• • HYDROCHLORIC ACID Salzsäure, Chlorwasserstoff
• • PHOSPHORIC ACID Phosphorsäure
• • POTASSIUM CITRATE Kaliumcitrat
• • POTASSIUM PHOSPHATE Kaliumdihydrogenphosphat
• • SODIUM ACETATE Natriumacetat, Natriumsalz der Essigsäure
• • SODIUM BICARBONATE Natriumbicarbonat, Natron, Natriumhydrogencarbonat
• • SODIUM CITRATE Natriumcitrat (Natriumsalz der Citronensäure)
• • SODIUM HYDROXIDE Natriumhydroxid, Natronlauge
• • SODIUM METAPHOSPHATE Natriummetaphosphat
• • SODIUM PHOSPHATE Natriumdihydrogenphosphat
• • SODIUM TRIMETAPHOSPHATE Trinatriumtrimetaphosphat
• • TETRAPOTASSIUM PYROPHOSPHATE Kaliumpyrophosphat
• • TETRASODIUM PYROPHOSPHATE Natriumpyrophosphat
• • TRIETHANOLAMINE Tris(2-hydroxyethyl)amin, Trihydroxytriethylamin Antioxidantien
• • ASCORBIC ACID Vitamin C, Ascorbinsäure
• • ASCORBYL PALMITATE Palmitinsäureascorbylester, L-Ascorbylpalmitat
• • BHT Butylhydroxytoluol, 2,6-Di-t-butyl-p-cresol
• • CAROTENOIDS Carotinoide
• • LYCOPENE Lycopin
• • TOCOPHEROL alpha-Tocopherol, Vitamin E
• • TOCOPHERYL ACETATE alpha-Tocopherylacetat (Vitamin-E-Acetat)
• • UBIQUINONE Q10, Coenzym Q10; Ubichinon-10
• • RUTIN Bindemittel
• • Alkydharze
• • Emulsionen
• • Epoxidharze
• • gebrannter Kalk, Zement, Lehm und Kaliwasserglas
• • Gummi arabicum
• • Harze
• • Honig
• • Kasein
• • Kunststoffdispersionen
• • Pflanzenöle (Leinöl, Avocadoöl, Weizenkeimöl, Mandelöl, Lavendelöl))
• • Polyurethane
• • Rosmarin
• • Silikonharz
• • Wachs
• • Zelluloseleim (Kleister) Farbstoffe/Farbpigmente
• • Natrium-4-[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo]-3-hydroxynaphthalin-1-sulfonat
• • Dihydroxyaluminiumstearat
• • Anthocyane (Cyanidin, Peonidin, Malvidin, Delphinidin, Petunidin, Pelargonidin)
• • Rote Bete; Rote Rübe; Zuckerrübe
• • Calciumstearat
• • Paprikaextrakt; Capsanthin, Capsorubin
• • Karamell, Zuckerkulör
• • 1,4-Bis(p-tolylamino)anthrachinon
• • Natrium-1-amino-4-(cyclohexylamino)-9,10-dihydro-9,10-dioxoanthracen-2-sulfonat
• • Indigo; 2-(1,3-Dihydro-3-oxo-2H-indazol-2-yliden)-1,2-dihydro-3H-indol-3-on
• • Dinatrium[29H,31H-phthalocyanindisulfonato(4-)-N29,N30,N31 ,N32]cuprat(2-)
• • Guanin; 2-Amino-6-hydroxypurin; 2-Amino-1,7-dihydro-6H-purin-6-on
• • Kurkumin, Curcumin; 1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-dien-3,5-dion
• • Karmin; Karminsäure
• • Chlorophyll; Chlorophyll a/b; Trinatrium-(2S-trans)-[18-carboxy-20-(carboxymethyl)-13-ethyl-2,3-dihydro-3,7,12,17-tetramethyl-8-vinyl-21H,23H-porphin-2-propionato(5-) N21, N22, N23, N24]cuprat(3-)
• • Aluminium
• • Aluminiumoxidhydrat; Aluminiumhydroxid
• • Wasserhaltiges Aluminiumsilicat
• • Calciumcarbonat; Kalziumkarbonat; Kreide
• • Calciumsulfat; Kalziumsulfat
• • Magnesiumcarbonat
• • LACTOFLAVIN Lactoflavin; Riboflavin
• • MAGNESIUM STEARATE Magnesiumdistearat
• • RIBOFLAVIN Riboflavin; Lactoflavin Feuchthaltemittel
• • CYCLOMETHICONE Cyclomethicon; besteht aus Octamethylcyclotetrasiloxan (D4), Decamethylcyclopentasiloxan (D5) und Dodecamethylcyclohexasiloxan (D6)
• • CYCLOPENTASILOXANE Decamethylcyclopentasiloxan
• • GLYCERIN Glycerin, Glycerol, 1,2,3-Propantriol
• • GLYCOL Glykol, Ethylenglycol, Ethylenglykol
• • LACTIC ACID Milchsäure; 2-Hydroxypropionsäure, 2-Hydroxypropansäure
• • y-6 Polyethylenglycol (durchschnittlich 6 Einheiten -CH2-CH2-O-)
• • SODIUM LACTATE Natriumlactat (Natriumsalz der Milchsäure)
• • SODIUM HYALURONATE
• • SORBITOL Sorbit, Sorbitol, Glucitol
• • PANTHENOL (Provitamin B5)
• • CAMELLIA EURYOIDES LEAF EXTRACT Harze
• • POLYMETHACRYLIC ACID Polymethacrylsäure
• • POLYVINYL ACETATE Polyvinylacetat
• • TOSYLAMIDE/FORMALDEHYDE RESIN Toluolsulfonamid-Formaldehydharz Konservierungsmittel
• • 4-HYDROXYBENZOIC ACID 4-Hydroxybenzoesäure
• • AMMONIUM BENZOATE Ammoniumbenzoat, Ammoniumsalz der Benzoesäure
• • AMMONIUM BISULFITE Ammoniumbisulfit, Ammoniumhydrogensulfit
• • AMMONIUM PROPIONATE Ammoniumpropionat, Ammoniumsalz der Propionsäure
• • AMMONIUM SULFITE Ammoniumsulfit
• • Benzethoniumchlorid
• • BENZOIC ACID Benzoesäure
• • BENZYL ALCOHOL Benzylalkohol; Phenylmethanol
• • BUTYL BENZOATE Benzoesäure-Butylester
• • BUTYLPARABEN Butylparaben; 4-Hydroxybenzoesäurebutylester
• • CALCIUM BENZOATE Calciumbenzoat, Calciumsalz der Benzoesäure
• • CALCIUM PARABEN 4-Hydroxybenzoesäure, Calciumsalz
• • CALCIUM PROPIONATE Calciumpropionat, Calciumsalz der Propionsäure
• • CALCIUM SALICYLATE Calciumsalicylat, Calciumsalz der Salicylsäure
• • CALCIUM SORBATE Calciumsorbat, Calciumsalz der Sorbinsäure
• • CETRIMONIUM CHLORIDE Cetrimoniumchlorid
• • DEHYDROACETIC ACID Dehydracetsäure, 3-Acetyl-6-methyl-2H-pyran-2,4(3H)-dion
• • DIAZOLIDINYL UREA Diazolidinylharnstoff
• • DMDM HYDANTOIN 1,3-Bis(hydroxymethyl)-5,5-dimethylimidazolidin-2,4-dion
• • ETHYL BENZOATE Benzoesäure-Ethylester
• • ETHYLPARABEN Ethylparaben; 4-Hydroxybenzoesäureethylester
• • FORMALDEHYDE Formaldehyd, Methanal, Formalin
• • FORMIC ACID Ameisensäure
• • GLUTARAL Glutaral, Glutardialdehyd
• • HEXAMIDINE Hexamidin
• • IMIDAZOLIDINYL UREA Imidazolidinyl-Harnstoff
• • IODOPROPYNYL BUTYLCARBAMATE 3-lod-2-propinylbutylcarbamat
• • ISOBUTYL BENZOATE Benzoesäure-Isobutylester
• • ISOPROPYL BENZOATE Benzoesäure-Isopropylester
• • ISOPROPYL CRESOLS 4-Isopropyl-m-cresol
• • MAGNESIUM BENZOATE Magnesiumbenzoat, Magnesiumsalz der Benzoesäure
• • MAGNESIUM PROPIONATE Magnesiumpropionat, Magnesiumsalz der Propionsäure
• • MAGNESIUM SALICYLATE Magnesiumsalicylat, Magnesiumsalz der Salicylsäure
• • MEA-BENZOATE Benzoesäure, (Mono-)Ethanolaminsalz
• • METHYL BENZOATE Benzoesäure-Methylester
• • METHYLISOTHIAZOLINONE Methylisothiazolinon, 2-Methyl-2H-isothiazol-3-on
• • METHYLPARABEN Methylparaben; 4-Hydroxybenzoesäuremethylester
• • O-PHENYLPHENOL o-Phenylphenol
• • PHENOXYETHANOL 2-Phenoxyethanol
• • PHENOXYISOPROPANOL Phenoxyisopropanol, 1-Phenoxypropan-2-ol
• • PHENYL BENZOATE Benzoesäure-Phenylester
• • PIROCTONE OLAMINE Pirocton-Olamin
• • POTASSIUM BENZOATE Kaliumbenzoat, Kaliumsalz der Benzoesäure
• • POTASSIUM BUTYLPARABEN Butylparaben (Kaliumsalz); 4-Hydroxybenzoesäurebutylester (Kaliumsalz)
• • POTASSIUM ETHYLPARABEN Ethylparaben (Kaliumsalz); 4-Hydroxybenzoesäureethylester (Kaliumsalz)
• • POTASSIUM METABISULFITE Dikaliumdisulfit
• • POTASSIUM METHYLPARABEN Methylparaben (Kaliumsalz); 4-Hydroxybenzoesäuremethylester (Kaliumsalz)
• • POTASSIUM PARABEN 4-Hydroxybenzoesäure, Kaliumsalz
• • POTASSIUM PROPIONATE Kaliumpropionat, Kaliumsalz der Propionsäure
• • POTASSIUM PROPYLPARABEN Propylparaben (Kaliumsalz); 4-Hydroxybenzoesäurepropylester (Kaliumsalz)
• • POTASSIUM SALICYLATE Kaliumsalicylat, Kaliumsalz der Salicylsäure
• • POTASSIUM SORBATE Kaliumsorbat, Kaliumsalz der Sorbinsäure
• • POTASSIUM SULFITE Kaliumsulfit
• • PROPIONIC ACID Propionsäure
• • PROPYL BENZOATE Benzoesäure-Propylester
• • PROPYLPARABEN Propylparaben; 4-Hydroxybenzoesäurepropylester
• • SODIUM BENZOATE Natriumbenzoat, Natriumsalz der Benzoesäure
• • SODIUM BISULFITE Natriumbisulfit, Natriumhydrogensulfit
• • SODIUM BUTYLPARABEN Butylparaben (Natriumsalz); 4-Hydroxybenzoesäurebutylester (Natriumsalz)
• • SODIUM ETHYLPARABEN Ethylparaben (Natriumsalz); 4-Hydroxybenzoesäureethylester (Natriumsalz)
• • SODIUM FORMATE Natriumformiat, Natriumsalz der Ameisensäure
• • SODIUM METABISULFITE Dinatriumdisulfit, Natriummetabisulfit
• • SODIUM METHYLPARABEN Methylparaben (Natriumsalz); 4-Hydroxybenzoesäuremethylester (Natriumsalz)
• • SODIUM PARABEN 4-Hydroxybenzoesäure, Natriumsalz
• • SODIUM PROPIONATE Natriumpropionat, Natriumsalz der Propionsäure
• • SODIUM PROPYLPARABEN Propylparaben (Natriumsalz); 4-Hydroxybenzoesäurepropylester (Natriumsalz)
• • SODIUM SALICYLATE Natriumsalicylat, Natriumsalz der Salicylsäure
• • SODIUM SORBATE Natriumsorbat, Natriumsalz der Sorbinsäure
• • SODIUM SULFITE Natriumsulfit
• • SORBIC ACID Sorbinsäure, 2,4-Hexadiensäure
• • STEARALKONIUM CHLORIDE Stearalkoniumchlorid
• • AMMONIUM PERSULFATE Ammoniumperoxodisulfat, Ammoniumpersulfat
• • HYDROGEN PEROXIDE Wasserstoffperoxid
• • POTASSIUM PERSULFATE Kaliumpersulfat, Kaliumperoxodisulfat
• • SODIUM PERSULFATE Natriumpersulfat, Natriumperoxodisulfat Reduktionsmittel
• • AMMONIUM BISULFITE Ammoniumbisulfit, Ammoniumhydrogensulfit
• • AMMONIUM THIOGLYCOLATE Ammoniumthioglycolat, Ammoniummercaptoacetat
• • SODIUM METABISULFITE Dinatriumdisulfit, Natriummetabisulfit
• • THIOGLYCOLIC ACID Thioglykolsäure, Thioglycolsäure; Mercaptoessigsäure
• • THIOLACTIC ACID Thiomlichsäure, 2-Mercaptopropionsäure Stabilisatoren
• • ACRYLATES/C10-30 ALKYL ACRYLATE CROSSPOLYMER Polymer aus Acrylsäurealkylestern (C10-C30), Acrylsäure, Methacrylsäure und/oder anderen Alkylacrylaten; kreuzverknpüft mit Propenyl-(allyl-)modifizierten Zuckern
• • ASCORBYL PALMITATE Palmitinsäureascorbylester, L-Ascorbylpalmitat
• • BENTONITE Bentonit (Tonmineral)
• • BHT Butylhydroxytoluol, 2,6-Di-t-butyl-p-cresol
• • CARBOMER Polyacrylsäure
• • CETEARYL ALCOHOL Cetearylalkohol, Mischung aus 1-Hexadecanol (Cetylalkohol) und 1-Octadecanol (Stearylalkohol)
• • CETYL HYDROXYETHYLCELLULOSE 2-Hydroxyethylcellulose-Cetyl-Ether
• • COCAMIDE MEA N-(Hydroxyethyl)-Kokosfettsäureamid
• • DISODIUM EDTA Ethylendiamintetraessigsäure, Dinatriumsalz
• • EDTA Ethylendiamintetraessigsäure
• • ETIDRONIC ACID Etidronsäure, 1-Hydroxyethyliden-bis-phosphonsäure
• • HYDROXYETHYLCELLULOSE Hydroxyethylcellulose
• • MICROCRYSTALLINE CELLULOSE Cellulose (mikrokristallin)
• • PENTASODIUM PENTETATE Pentanatrium(carboxylatomethyl)iminobis(ethylennitrilo)tetraacetat
• • POTASSIUM ALGINATE Kaliumalginat (Kaliumsalz der Alginsäure)
• • PVP Polyvinylpyrrolidon
• • SODIUM CARBOMER Polyacrylsäure (Natriumsalze)
• • SODIUM CITRATE Natriumcitrat (Natriumsalz der Citronensäure)
• • SODIUM GLUCONATE Natriumgluconat (Natriumsalz der Gluconsäure)
• • TETRASODIUM EDTA Ethylendiamintetraessigsäure, Tetranatriumsalz
• • TOCOPHEROL alpha-Tocopherol, Vitamin E
• • TRISODIUM EDTA Ethylendiamintetraessigsäure, Trinatriumsalz
• • Polysaccharide Treibgase für Sprays
• • Butan
• • Kohlendioxid
• • Dimethylether
• • Isobutan, 2-Methylpropan
• • Stickstoff
• • Propan

Alkalizing agents/acids/neutralizing agents

• • ACETIC ACID Acetic acid
• • AMINOMETHYL PROPANOL 2-amino-2-methylpropanol
• • AMMONIA Ammonia
• • AMMONIUM BICARBONATE Ammonium bicarbonate, ammonium bicarbonate
• • AMMONIUM CARBONATE Ammonium carbonate
• • CITRIC ACID citric acid, citric acid
• • DISODIUM PHOSPHATE disodium hydrogen phosphate
• • DISODIUM PYROPHOSPHATE disodium dihydrogen pyrophosphate
• • ETHANOLAMINE Ethanolamine, 2-aminoethanol
• • HYDROCHLORIC ACID hydrochloric acid, hydrogen chloride
• • PHOSPHORIC ACID Phosphoric acid
• • POTASSIUM CITRATE Potassium citrate
• • POTASSIUM PHOSPHATE Potassium dihydrogen phosphate
• • SODIUM ACETATE Sodium acetate, sodium salt of acetic acid
• • SODIUM BICARBONATE Sodium bicarbonate, baking soda, sodium bicarbonate
• • SODIUM CITRATE Sodium citrate (sodium salt of citric acid)
• • SODIUM HYDROXIDE Sodium hydroxide, caustic soda
• • SODIUM METAPHOSPHATE Sodium metaphosphate
• • SODIUM PHOSPHATE Sodium dihydrogen phosphate
• • SODIUM TRIMETAPHOSPHATE Trisodium trimetaphosphate
• • TETRAPOTASSIUM PYROPHOSPHATE Potassium pyrophosphate
• • TETRASODIUM PYROPHOSPHATE Sodium pyrophosphate
• • TRIETHANOLAMINE Tris(2-hydroxyethyl)amine, trihydroxytriethylamine antioxidants
• • ASCORBIC ACID Vitamin C, ascorbic acid
• • ASCORBYL PALMITATE Ascorbyl Palmitate, L-Ascorbyl Palmitate
• • BHT butylated hydroxytoluene, 2,6-di-t-butyl-p-cresol
• • CAROTENOIDS Carotenoids
• • LYCOPENE Lycopene
• • TOCOPHEROL alpha-tocopherol, vitamin E
• • TOCOPHERYL ACETATE alpha-tocopheryl acetate (vitamin E acetate)
• • UBIQUINONE Q10, coenzyme Q10; ubiquinone-10
• • RUTIN binder
• • alkyd resins
• • Emulsions
• • Epoxy resins
• • burnt lime, cement, clay and potash water glass
• • Gum arabic
• • resins
• • Honey
• • Casein
• • Plastic dispersions
• • Vegetable oils (linseed oil, avocado oil, wheat germ oil, almond oil, lavender oil))
• • Polyurethanes
• • Rosemary
• • Silicone resin
• • Wax
• • cellulose glue (paste) dyes/color pigments
• • Sodium 4-[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo]-3-hydroxynaphthalene-1-sulfonate
• • Dihydroxyaluminum stearate
• • Anthocyanins (cyanidin, peonidin, malvidin, delphinidin, petunidin, pelargonidin)
• • Beetroot; Red beet; sugar beet
• • Calcium stearate
• • paprika extract; capsanthin, capsorubin
• • Caramel, caramel
• • 1,4-bis(p-tolylamino)anthraquinone
• • Sodium 1-amino-4-(cyclohexylamino)-9,10-dihydro-9,10-dioxoanthracene-2-sulfonate
• • indigo; 2-(1,3-Dihydro-3-oxo-2H-indazol-2-ylidene)-1,2-dihydro-3H-indol-3-one
• • disodium[29H,31H-phthalocyaninedisulfonato(4-)-N29,N30,N31 ,N32]cuprate(2-)
• • guanine; 2-amino-6-hydroxypurine; 2-amino-1,7-dihydro-6H-purin-6-one
• • curcumin, curcumin; 1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
• • carmine; carminic acid
• • chlorophyll; chlorophyll a/b; Trisodium (2S-trans)-[18-carboxy-20-(carboxymethyl)-13-ethyl-2,3-dihydro-3,7,12,17-tetramethyl-8-vinyl-21H,23H-porphine-2 -propionato(5-) N21, N22, N23, N24]cuprate(3-)
• • Aluminum
• • alumina hydrate; aluminum hydroxide
• • Hydrous aluminum silicate
• • calcium carbonate; Calcium carbonate; chalk
• • calcium sulfate; calcium sulfate
• • Magnesium carbonate
• • LACTOFLAVIN Lactoflavin; riboflavin
• • MAGNESIUM STEARATE Magnesium distearate
• • RIBOFLAVIN riboflavin; Lactoflavin humectant
• • CYCLOMETHICONE cyclomethicone; consists of octamethylcyclotetrasiloxane (D4), decamethylcyclopentasiloxane (D5) and dodecamethylcyclohexasiloxane (D6)
• • CYCLOPENTASILOXANES Decamethylcyclopentasiloxane
• • GLYCEROL Glycerol, glycerol, 1,2,3-propanetriol
• • GLYCOL Glycol, Ethylene Glycol, Ethylene Glycol
• • LACTIC ACID lactic acid; 2-Hydroxypropionic Acid, 2-Hydroxypropanoic Acid
• • y-6 polyethylene glycol (average 6 units -CH2-CH2-O-)
• • SODIUM LACTATE Sodium lactate (sodium salt of lactic acid)
• • SODIUM HYALURONATE
• • SORBITOL sorbitol, sorbitol, glucitol
• • PANTHENOL (provitamin B5)
• • CAMELLIA EURYOIDES LEAF EXTRACT resins
• • POLYMETHACRYLIC ACID Polymethacrylic acid
• • POLYVINYL ACETATE Polyvinyl acetate
• • TOSYLAMIDE/FORMALDEHYDE RESIN Toluenesulfonamide-formaldehyde resin preservative
• • 4-HYDROXYBENZOIC ACID 4-hydroxybenzoic acid
• • AMMONIUM BENZOATE Ammonium benzoate, ammonium salt of benzoic acid
• • AMMONIUM BISULFITE Ammonium bisulfite, ammonium hydrogen sulfite
• • AMMONIUM PROPIONATE Ammonium propionate, ammonium salt of propionic acid
• • AMMONIUM SULFITE Ammonium sulfite
• • Benzethonium chloride
• • BENZOIC ACID benzoic acid
• • BENZYL ALCOHOL benzyl alcohol; phenylmethanol
• • BUTYL BENZOATE Benzoic acid butyl ester
• • BUTYLPARBEN butylparaben; 4-Hydroxybenzoic acid butyl ester
• • CALCIUM BENZOATE Calcium benzoate, calcium salt of benzoic acid
• • CALCIUM PARABEN 4-Hydroxybenzoic acid, calcium salt
• • CALCIUM PROPIONATE Calcium propionate, calcium salt of propionic acid
• • CALCIUM SALICYLATE Calcium salicylate, calcium salt of salicylic acid
• • CALCIUM SORBATE Calcium sorbate, calcium salt of sorbic acid
• • CETRIMONIUM CHLORIDE Cetrimonium chloride
• • DEHYDROACETIC ACID Dehydroacetic acid, 3-acetyl-6-methyl-2H-pyran-2,4(3H)-dione
• • DIAZOLIDINYL UREA Diazolidinyl urea
• • DMDM HYDANTOIN 1,3-bis(hydroxymethyl)-5,5-dimethylimidazolidine-2,4-dione
• • ETHYL BENZOATE Benzoic acid ethyl ester
• • ETHYLPARABEN ethylparaben; 4-Hydroxybenzoic acid ethyl ester
• • FORMALDEHYDE Formaldehyde, methanal, formalin
• • FORMIC ACID formic acid
• • GLUTARAL Glutaral, glutaric dialdehyde
• • HEXAMIDINE Hexamidine
• • IMIDAZOLIDINYL UREA Imidazolidinyl urea
• • IODOPROPYNYL BUTYLCARBAMATE 3-iodo-2-propynylbutylcarbamate
• • ISOBUTYL BENZOATE Isobutyl benzoate
• • ISOPROPYL BENZOATE Isopropyl benzoate
• • ISOPROPYL CRESOLS 4-isopropyl-m-cresol
• • MAGNESIUM BENZOATE Magnesium benzoate, magnesium salt of benzoic acid
• • MAGNESIUM PROPIONATE Magnesium propionate, magnesium salt of propionic acid
• • MAGNESIUM SALICYLATE Magnesium salicylate, magnesium salt of salicylic acid
• • MEA-BENZOATE Benzoic acid, (mono)ethanolamine salt
• • METHYL BENZOATE Benzoic acid methyl ester
• • METHYLISOTHIAZOLINONE Methylisothiazolinone, 2-Methyl-2H-isothiazol-3-one
• • METHYLPARABEN methylparaben; Methyl 4-hydroxybenzoate
• • O-PHENYLPHENOL o-Phenylphenol
• • PHENOXYETHANOL 2-Phenoxyethanol
• • PHENOXYISOPROPANOL phenoxyisopropanol, 1-phenoxypropan-2-ol
• • PHENYL BENZOATE Benzoic acid phenyl ester
• • PIROCTONE OLAMINE Piroctone olamine
• • POTASSIUM BENZOATE Potassium benzoate, the potassium salt of benzoic acid
• • POTASSIUM BUTYLPARBEN butylparaben (potassium salt); 4-Hydroxybenzoic acid butyl ester (potassium salt)
• • POTASSIUM ETHYLPARABEN ethylparaben (potassium salt); 4-Hydroxybenzoic acid ethyl ester (potassium salt)
• • POTASSIUM METABISULPHITE Dipotassium metabisulfite
• • POTASSIUM METHYLPARABEN methylparaben (potassium salt); Methyl 4-hydroxybenzoate (potassium salt)
• • POTASSIUM PARABEN 4-Hydroxybenzoic acid, potassium salt
• • POTASSIUM PROPIONATE Potassium propionate, potassium salt of propionic acid
• • POTASSIUM PROPYLPARABEN propylparaben (potassium salt); 4-Hydroxybenzoic acid propyl ester (potassium salt)
• • POTASSIUM SALICYLATE Potassium salicylate, the potassium salt of salicylic acid
• • POTASSIUM SORBATE Potassium sorbate, potassium salt of sorbic acid
• • POTASSIUM SULFITE Potassium sulfite
• • PROPIONIC ACID Propionic acid
• • PROPYL BENZOATE Benzoic acid propyl ester
• • PROPYLPARABEN propylparaben; 4-Hydroxybenzoic acid propyl ester
• • SODIUM BENZOATE Sodium benzoate, sodium salt of benzoic acid
• • SODIUM BISULFITE Sodium bisulfite, sodium hydrogen sulfite
• • SODIUM BUTYLPARBEN butylparaben (sodium salt); 4-Hydroxybenzoic acid butyl ester (sodium salt)
• • SODIUM ETHYLPARABEN Ethylparaben (sodium salt); 4-Hydroxybenzoic acid ethyl ester (sodium salt)
• • SODIUM FORMAT Sodium formate, sodium salt of formic acid
• • SODIUM METABISULFITE disodium metabisulfite, sodium metabisulfite
• • SODIUM METHYLPARABEN Methylparaben (sodium salt); Methyl 4-hydroxybenzoate (sodium salt)
• • SODIUM PARABEN 4-Hydroxybenzoic acid, sodium salt
• • SODIUM PROPIONATE Sodium propionate, sodium salt of propionic acid
• • SODIUM PROPYLPARABEN Propylparaben (sodium salt); 4-Hydroxybenzoic acid propyl ester (sodium salt)
• • SODIUM SALICYLATE Sodium salicylate, sodium salt of salicylic acid
• • SODIUM SORBATE Sodium sorbate, sodium salt of sorbic acid
• • SODIUM SULFITE Sodium sulfite
• • SORBIC ACID Sorbic acid, 2,4-hexadienoic acid
• • STEARALKONIUM CHLORIDES stearalkonium chloride
• • AMMONIUM PERSULFATE Ammonium peroxodisulphate, ammonium persulphate
• • HYDROGEN PEROXIDE Hydrogen peroxide
• • POTASSIUM PERSULFATE Potassium persulphate, potassium peroxodisulphate
• • SODIUM PERSULFATE Sodium persulphate, sodium peroxodisulphate reducing agent
• • AMMONIUM BISULFITE Ammonium bisulfite, ammonium hydrogen sulfite
• • AMMONIUM THIOGLYCOLATE Ammonium thioglycolate, ammonium mercaptoacetate
• • SODIUM METABISULFITE disodium metabisulfite, sodium metabisulfite
• • THIOGLYCOLIC ACID thioglycolic acid, thioglycolic acid; mercaptoacetic acid
• • THIOLACTIC ACID Thiomic acid, 2-mercaptopropionic acid stabilizers
• • ACRYLATES/C10-30 ALKYL ACRYLATE CROSSPOLYMER Polymer of acrylic acid alkyl esters (C10-C30), acrylic acid, methacrylic acid and/or other alkyl acrylates; cross-linked with propenyl (allyl) modified sugars
• • ASCORBYL PALMITATE Ascorbyl Palmitate, L-Ascorbyl Palmitate
• • BENTONITE Bentonite (clay mineral)
• • BHT butylated hydroxytoluene, 2,6-di-t-butyl-p-cresol
• • CARBOMER polyacrylic acid
• • CETEARYL ALCOHOL Cetearyl alcohol, mixture of 1-hexadecanol (cetyl alcohol) and 1-octadecanol (stearyl alcohol)
• • CETYL HYDROXYETHYLCELLULOSE 2-hydroxyethylcellulose cetyl ether
• • COCAMIDE MEA N-(Hydroxyethyl) Coconut Fatty Acid Amide
• • DISODIUM EDTA Ethylenediaminetetraacetic acid, disodium salt
• • EDTA ethylenediaminetetraacetic acid
• • ETIDRONIC ACID Etidronic acid, 1-hydroxyethylidene bisphosphonic acid
• • HYDROXYETHYLCELLULOSE Hydroxyethyl cellulose
• • MICROCRYSTALLINE CELLULOSE cellulose (microcrystalline)
• • PENTASODIUM PENTETATE Pentasodium(carboxylatomethyl)iminobis(ethylenenitrilo)tetraacetate
• • POTASSIUM ALGINATE Potassium alginate (potassium salt of alginic acid)
• • PVP polyvinylpyrrolidone
• • SODIUM CARBOMER polyacrylic acid (sodium salts)
• • SODIUM CITRATE Sodium citrate (sodium salt of citric acid)
• • SODIUM GLUCONATE Sodium gluconate (sodium salt of gluconic acid)
• • TETRASODIUM EDTA Ethylenediaminetetraacetic acid, tetrasodium salt
• • TOCOPHEROL alpha-tocopherol, vitamin E
• • TRISODIUM EDTA Ethylenediaminetetraacetic acid, trisodium salt
• • Polysaccharide propellants for sprays
• • Butane
• • Carbon Dioxide
• • dimethyl ether
• • Isobutane, 2-methylpropane
• • Nitrogen
• • Propane

opacifiers/pearlizers

• • Calcium Sulphate
• • cellulose
• • GLYCOL PALMITATES palmitic acid glycol ester; 2-Hydroxyethyl Palmitate
• • MICA Mica (a silicate mineral)
• • PEG-2 STEARATES 2-(2-hydroxyethoxy)ethyl stearate; Esters of stearic acid and diethylene glycol (1:1)
• • PROPYLENE GLYCOL DISTEARATE propylene glycol distearate; Esters of stearic acid and propylene glycol (2:1)
• • PROPYLENE GLYCOL STEARATE SE propylene glycol stearate; Ester of stearic acid and propylene glycol (1:1), contains sodium or potassium stearate denaturant plasticizer
• • BUTYL STEARATES butyl stearate, butyl stearate
• • CAMPHOR Fighter
• • CETEARYL ISONONANOATES Cetearyl isononanoate, esters of isononanoic acid and cetearyl alcohol
• • DIBUTYL SEBACATE Dibutyl sebacate, dibutyl sebacate
• • DICAPRYLYL ETHER dicaprylyl ether, dioctyl ether
• • DIISODECYL ADIPATE Diisodecyl adipate, adipic acid diisodecyl ester
• • ISOPROPYL CITRATE Isopropyl citrate, isopropyl citric acid
• • ISOPROPYL MYRISTATE isopropyl myristate, myristic acid isopropyl ester
• • ISOPROPYL PALMITATE Isopropyl Palmitate, Palmitic Acid Isopropyl Ester
• • OCTYLDODECANOL 2-Octyldodecan-1-ol
• • SORBITOL sorbitol, sorbitol, glucitol
• • TOSYLAMIDE/FORMALDEHYDE RESIN
• • Toluenesulfonamide formaldehyde resin
• • Minerals
• • Sand
• • Vitamins: Vitamin A, Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B4, Vitamin B5, Vitamin B6, Vitamin B7, Vitamin B8, Vitamin B9, Vitamin B12, Vitamin C, Vitamin D, Vitamin E, Vitamin K
• • Salt: Table salt, Himalayan salt, Hawaiian salt, Dead Sea salt
• • micelles

Moisturizing substances:

• • SQUALANE 2,6,10,15,19,23-Hexamethyltetracosan
• • SQUALENE 2,6,10,15,19,23-Hexamethyl-2,6,10,14,18,22-tetracosahexaen
• • STEARETH-10 Polyethylenglycolether des Stearylakohols (durchschnittlich 10 Einheiten -CH₂-CH₂-O-)
• • STEARYL ALCOHOL Stearylalkohol, 1-Octadecanol
• • TRIMYRISTIN Glyceryl-Trimyristat; Veresterungsprodukt von Glycerin und Myristinsäure (1:3)
• • TRIPALMITIN
• • Eucerit, Wollwachsalkohole Glyceryl-Tripalmitat; Veresterungsprodukt von Glycerin und Palmitinsäure (1:3)
• • WHEAT GERM GLYCERIDES Veresterungsprodukt von Glycerin und Fettsäuren aus Weizenkeimöl

Moisturizing substances, also called moisturizing agents and/or moisturizing agents, are substances that are usually added to surfactant preparations to counteract their degreasing character. The following moisturizing substances are used for this. The list below is exemplary and not exhaustive. On the basis of his general specialist knowledge, the person skilled in the art can readily name further possible moisturizing substances.

• • SQUALANE 2,6,10,15,19,23-hexamethyltetracosane
• • SQUALENE 2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaene
• • STEARETH-10 polyethylene glycol ether of stearyl alcohol (average 10 units -CH ₂ -CH ₂ -O-)
• • STEARYL ALCOHOL Stearyl alcohol, 1-octadecanol
• • TRIMYRISTIN glyceryl trimyristate; Esterification product of glycerol and myristic acid (1:3)
• • TRIPALMITE
• • Eucerit, wool wax alcohols glyceryl tripalmitate; Esterification product of glycerol and palmitic acid (1:3)
• • WHEAT GERM GLYCERIDES Esterification product of glycerol and fatty acids from wheat germ oil

oils:

• • BETULA ALBA BARK EXTRACT (Birke)
• • CAPRYLIC/CAPRIC TRIGLYCERIDE Veresterungsprodukt von Glycerin und Caprinsäure sowie Caprylsäure (1:3)
• • CETEARYL ALCOHOL Cetearylalkohol, Mischung aus 1-Hexadecanol (Cetylalkohol) und 1-Octadecanol (Stearylalkohol)
• • CYCLOMETHICONE Cyclomethicon; besteht aus Octamethylcyclotetrasiloxan (D4), Decamethylcyclopentasiloxan (D5) und Dodecamethylcyclohexasiloxan (D6)
• • DIBUTYL SEBACATE Dibutylsebacat, Sebacinsäuredibutylester
• • DICAPRYLYL ETHER Dicaprylylether, Dioctylether
• • DIISODECYL ADIPATE Diisodecyladipat, Adipinsäure-Diisodecylester
• • DIMETHICONE Polydimethylsiloxan
• • GLYCERYLSTEARATE Glycerinstearat, Glycerinmonostearat, Stearinsäure-Glycerinester
• • ISOPROPYL MYRISTATE Isopropylmyristat, Myristinsäure-Isopropylester
• • ISOPROPYL PALMITATE Isopropylpalmitat, Palmitinsäure-Isopropylester
• • KAKAO-BUTTER
• • MACADAMIA INTEGRIFOLIA SEED OIL Macadamia; Macadamianuss, echte; Macadamianussöl
• • MACADAMIA TERNIFOLIA SEED OIL Macadamia, dreiblättrige; Macadamianussöl
• • OCTYLDODECANOL 2-Octyldodecan-1-ol
• • PARAFFIN Hartparaffin, Mikrokristallines Wachs, Ozokerit, Ceresin, Vaselin
• • PARAFFINUM LIQUIDUM Flüssiges Paraffin, Paraffinöl, Mineralöl
• • PERSEA GRATISSIMA OIL Avocado; Avocadoöl
• • SHEA-BUTTER
• • SIMMONDSIA CHINENSIS SEED OIL Jojobastrauch; Jojobaöl
• • STEARIC ACID n-Octadecansäure, Octadecansäure, Stearinsäure Duft- und/oder Aromastoffe

Oils are a collective term for different liquid fatty substances. These include, inter alia, mineral oils, silicone oils and/or oils of natural origin, such as vegetable oils and/or essential oils. These are often characterized by mono- and/or polyunsaturated fatty acids. Oils of animal origin are usually referred to as fats. In addition, many oil components used in cosmetics are synthetically produced on the basis of natural raw materials. Just like the moisturizing substances, oil components prevent the skin and/or hair from drying out prematurely. In the list below, the oils are given as examples and are not exhaustive. On the basis of his general specialist knowledge, the person skilled in the art can readily name further possible oils.

• • BETULA ALBA BARK EXTRACT (Birch)
• • CAPRYLIC/CAPRIC TRIGLYCERIDE Esterification product of glycerol and capric acid as well as caprylic acid (1:3)
• • CETEARYL ALCOHOL Cetearyl alcohol, mixture of 1-hexadecanol (cetyl alcohol) and 1-octadecanol (stearyl alcohol)
• • CYCLOMETHICONE cyclomethicone; consists of octamethylcyclotetrasiloxane (D4), decamethylcyclopentasiloxane (D5) and dodecamethylcyclohexasiloxane (D6)
• • DIBUTYL SEBACATE Dibutyl sebacate, dibutyl sebacate
• • DICAPRYLYL ETHER Dicaprylyl ether, dioctyl ether
• • DIISODECYL ADIPATE Diisodecyl adipate, adipic acid diisodecyl ester
• • DIMETHICONE Polydimethylsiloxane
• • GLYCERYL STEARATE Glycerol stearate, glycerol monostearate, stearic acid glycerol ester
• • ISOPROPYL MYRISTATE Isopropyl myristate, myristic acid isopropyl ester
• • ISOPROPYL PALMITATE Isopropyl palmitate, palmitic acid isopropyl ester
• • COCOA BUTTER
• • MACADAMIA INTEGRIFOLIA SEED OIL macadamia; macadamia nut, real; macadamia nut oil
• • MACADAMIA TERNIFOLIA SEED OIL Macadamia, trifoliate; macadamia nut oil
• • OCTYLDODECANOL 2-Octyldodecan-1-ol
• • PARAFFIN Hard paraffin, microcrystalline wax, ozokerite, ceresin, vaseline
• • PARAFFINUM LIQUIDUM Liquid paraffin, paraffin oil, mineral oil
• • PERSEA GRATISSIMA OIL Avocado; avocado oil
• • SHEA BUTTER
• • SIMMONDSIA CHINENSIS SEED OIL jojoba shrub; jojoba oil
• • STEARIC ACID n-octadecanoic acid, octadecanoic acid, stearic acid Fragrances and/or flavorings

Essential oils, aromas, fragrances and perfumes:

Essential oils are volatile, intensely smelling mixtures of substances with an oily consistency that are difficult to dissolve in water. They are usually obtained from plant raw materials by steam distillation. They can also be obtained by synthesis, extraction or by pressing. Pure plant substances such as menthol, cineol, vanillin and/or thymol are also referred to as essential oils. In medicine, depending on the oil, they are used to treat numerous ailments, e.g. for muscle and joint pain, infectious diseases, colds and complaints in the gastrointestinal tract. They are also used in cosmetics, especially for perfuming.

Flavorings are products that are added to foods, for example, to give them a particular smell and/or taste. An aroma can be made up of numerous aromatic substances, Aro ma extracts, thermally obtained reaction aromas, smoke aromas and/or aroma precursors. Most flavors are used industrially in food production, some flavors are also available in retail. Flavorings are chemically defined substances with flavoring properties (aroma properties) that are used to produce flavors. A distinction is made between natural, nature-identical and/or artificial flavorings.

Fragrances used in cosmetics are, on the one hand, organic compounds from the animal and plant kingdoms. Furthermore, fragrances are compounds that can be produced synthetically. The purpose of the fragrances in cosmetic products is to mask the product's own odor and continue to trigger pleasant sensations in the consumer. Perfumes in the narrower sense are fragrances and fragrance mixtures that are intended to change or mask body odor.

The list of Essential Oils, Flavors, Fragrances and Perfumes below is exemplary and not exhaustive. On the basis of his general specialist knowledge, the person skilled in the art can readily name further possible essential oils, aromas and/or fragrances and/or perfumes.

Essential Oils:

• • CAMPHOR Fighter
• • CINNAMOMUM ZEYLANICUM LEAF OIL Ceylon cinnamon tree; cinnamon laurel tree
• • CITRUS LIMON PEEL OIL Lemon Tree; lemon
• • EUCALYPTOL eucalyptol; 3,3-trimethyl-2-oxabicyclo[2.2.2]octane, 1,8-cineole
• • JASMINUM OFFICINALE FLOWER EXTRACT jasmine
• • LAVANDULA ANGUSTIFOLIA OIL Lavender real
• • ALMOND OIL (Sweet Almond oil)
• • MENTHOL Menthol; 5-Methyl-2-(1-methylethyl)cyclohexanol
• • PINUS SYLVESTRIS LEAF OIL pine, mean
• • VANILLIN vanillin

flavorings

• • AROMA flavouring, mixture of flavours
• • MENTHOL Menthol; 5-Methyl-2-(1-methylethyl)cyclohexanol
• • VANILLIN vanillin

perfumes and/or fragrances

• • ANISE ALCOHOL anise alcohol; anisyl alcohol, 4-methoxybenzyl alcohol
• • BENZYL ALCOHOL benzyl alcohol; phenylmethanol
• • CINNAMOMUM ZEYLANICUM LEAF OIL cinnamon tree; cinnamon laurel tree
• • CITRUS LIMON PEEL OIL Lemon Tree; lemon
• • EUCALYPTOL eucalyptol; 3,3-trimethyl-2-oxabicyclo[2.2.2]octane, 1,8-cineole
• • JASMINUM OFFICINALE FLOWER EXTRACT jasmine
• • METHYLPHENYLBUTANOL 2-methyl-4-phenylbutan-2-ol
• • OCTYLDODECANOL 2-octyldodecan-1-ol
• • PERFUME

Perfumes, fragrances and fragrance blends

• • PINK INDICA FLOWER EXTRACT tea rose
• • PINK CENTIFOLIA rose water
• • LIMONENE Limonene, carvene, p-mentha-1,8-diene, 1-methyl-4-prop-1-en-2-yl-cyclohexene, 1-methyl-4-isopropenyl-1-cyclohexene

Moisturizers:

• • ALOE BARBADENSIS LEAF JUICE aloe vera; gel/juice
• • ALOE BARBADENSIS LEAF JUICE POWDER aloe vera
• • Collagen
• • GLYCERIN glycerin
• • HYALURONIC ACID hyaluronic acid
• • LACTIC ACID lactic acid; 2-Hydroxypropionic Acid, 2-Hydroxypropanoic Acid
• • SODIUM HYALURONATE Sodium hyaluronate (sodium salt of hyaluronic acid)
• • SODIUM LACTATE Sodium lactate (sodium salt of lactic acid)
• • UREA urea
• • ALGAE (algae)
• • ECHINACEA PURPUREA EXTRACT

Active ingredients for the skin:

• • ALLANTOIN Glyoxylic acid diureide, 5-ureidohydantoin, N-(2,5-dioxo-4-imidazolidinyl)urea
• • ALOE BARBADENSIS LEAF JUICE Aloe Vera; gel/juice
• • ASCORBIC ACID vitamin C, ascorbic acid
• • BISABOLOL alpha-bisabolol, ®-6-methyl-2-(®-4-methylcyclohex-3-enyl)hept-5-en-2-ol
• • C12-15 ALKYL BENZOATES Esters of benzoic acid and fatty alcohols with a chain length of C12 to C15
• • CAPRYLIC/CAPRIC TRIGLYCERIDES Esterification product of glycerol with capric acid and caprylic acid (1:3)
• • CHAMOMILLA RECUTITA FLOWER EXTRACT chamomile, real
• • DECYLOLEATE decyl oleate; Esterification product of oleic acid with decyl alcohol
• • DIETHYLHEXYL SYRINGYLIDENEMALONATE [(4-Hydroxy-3,5-dimethoxyphenyl)methylene]propanedioic acid, bis(2-ethylhexyl) ester
• • ETHYLHEXYL COCOATE Esterification product from 2-ethylhexanol and coconut fatty acids
• • ETHYLHEXYL STEARATE stearic acid 2-ethylhexyl ester
• • ETHYLHEXYLGLYCEROL ethylhexylglycerol; 3-(2-ethylhexyloxy)-1,2-propanediol
• • FAGUS SILVATICA (beech)
• • HYALURONIC ACID hyaluronic acid
• • NIACINAMIDES Niacinamide, 3-pyridinecarboxamide, pyridine-3-carboxamide, nicotinamide, nicotinamide
• • PANTHENOL Dexpanthenol, provitamin B5
• • PERSEA GRATISSIMA OIL Avocado; avocado oil
• • PPG-15 STEARYL ETHER Stearyl alcohol etherified with polypropylene glycol (average 15 units propylene glycol)
• • PROPYL HEPTYL CAPRYLATE Esterification product of 2-propylheptanol with caprylic acid
• • SIMMONDSIA CHINENSIS SEED OIL jojoba bush; jojoba oil
• • SODIUM HYALURONATE Sodium hyaluronate (sodium salt of hyaluronic acid)
• • STEARYL DIMETHICONE poly(dimethyl-methylstearyl)siloxane
• • SUCROSE LAURATE Esterification product of lauric acid with sucrose (cane sugar)
• • TOCOPHEROL alpha-tocopherol, vitamin E
• • UBIQUINONE Q10, coenzyme Q10; ubiquinone-10
• • HELIANTHUS ANNUUS HYBRID OIL
• • ECHIUM PLANTAGINEUM SEED OIL
• • CARDIOSPERMUM HALICACABUM FLOWER/LEAF/VINE EXTRACT
• • RUTIN
• • ARGININE

Deodorizing active ingredients:

• • FARNESOL farnesol, 3,7,11-trimethyl-2,6,10-dodecatrien-1-ol
• • PERFUME Perfume; fragrances and fragrance mixtures
• • TRICLOSAN triclosan, 5-chloro-2-(2,4-dichlorophenoxy)phenol
• • TRIETHYL CITRATE triethyl citrate; citric acid triethyl ester
• • ZINC LACTATE zinc lactate (zinc salt of lactic acid)
• • ZINC RICINOLATE zinc ricinoleate

Solvent:

• • 1,2-HEXANEDIOL 1,2-hexanediol; 1,2-dihydroxyhexane
• • ACETONES acetone, propanone
• • ALCOHOL alcohol, ethanol, ethanol, ethyl alcohol
• • ALCOHOL DENAT denatured alcohol, denatured alcohol
• • AQUA Water
• • BUTYL ACETATE butyl acetate, butyl acetate
• • BUTYLENE GLYCOL 1,3-butanediol, butylene glycol
• • CYCLOPENTASILOXANES decamethylcyclopentasiloxane
• • ETHYL ACETATE ethyl acetate, ethyl acetate
• • GLYCERIN Glycerin, Glycerol, 1,2,3-Propanetriol
• • GLYCOL glycol, ethylene glycol, ethylene glycol
• • ISOPROPYL ALCOHOL isopropyl alcohol, isopropanol, 2-propanol
• • METHYLPROPANEDIOL 2-methyl-1,3-propanediol
• • PROPYLENE GLYCOL 1,2-propanediol, propylene glycol
• • ECHIUM PLANTAGINEUM SEED OIL

filmmaker:

• • ACRYLATES COPOLYMER Polymer of methacrylic acid, ethyl acrylate and methyl methacrylate
• • ACRYLATES/HYDROXYESTERS ACRYLATES COPOLYMER Copolymer of acrylic acid/methacrylic acid and their esters and hydroxyacrylic acid esters
• • ACRYLATES/STEARETH-20 METHACRYLATE CROSSPOLYMER Copolymer of steareth-20 methacrylate and acrylic acid/methacrylic acid and their esters cross-linked with pentaerythritol allyl ether. Steareth-20 methacrylate is an ester of methacrylic acid with polyethylene glycol (average 20 units -CH ₂ -CH ₂ -O-)
• • DIBUTYL SEBACATE Dibutyl sebacate, dibutyl sebacate
• • NITROCELLULOSE Nitrocellulose, cellulose nitrate, guncotton
• • PVP polyvinylpyrrolidone
• • SODIUM CARBOMER polyacrylic acid (sodium salts)
• • TOSYLAMIDE/FORMALDEHYDE RESIN Toluenesulfonamide formaldehyde resin
• • PHTHALIC ANHYDRIDE/TRIMELLITIC ANHYDRIDE/GLYCOLS COPOLYMER

gelling agent:

• • AGAR Agar, agar-agar
• • ALGIN Sodium alginate (sodium salt of alginic acid)
• • ALGINIC ACID alginic acid
• • CARBOMER polyacrylic acid
• • CARRAGEENAN Moss, Irish; carrageenan
• • HECTORITE Hectorite (clay mineral)
• • HYDROXYETHYLCELLULOSE hydroxyethyl cellulose
• • HYDROXYPROPYLCELLULOSE hydroxypropyl cellulose
• • POLYVINYL ALCOHOL polyvinyl alcohol
• • PVP polyvinylpyrrolidone
• • SODIUM CARBOMER polyacrylic acid (sodium salts)
• • STEARALKONIUM HECTORITE

Tanning substances, tanning centers and/or tanning extracts:

A distinction is made between tanning agents, tanning agents and/or tanning extracts. Tanning agents are chemical substances used to tan animal hides. The treatment with tanning agents converts the animal skins into leather, which among other things prevents rotting. There are also naturally occurring, i.e. natural, and artificially produced, i.e. synthetic tanning agents. Tanning agents are parts of plants and/or mixtures of substances that contain one and/or more tanning agents. The terms tanning agent and/or tanning agent are often used as synonyms. A tanning extract is an extract of a tanning agent. After the extraction, the tanning agent is present in a higher concentration, without any disturbing components of the starting material. Vegetable tanning agents, also called tannins, are also used in medicine. Furthermore, tannins are known as flavor components of wine and tea.

Examples of suitable tanning agents:

• • Gallotannins
• • Pyrocatechins
• • Catechin
• • mineral tanning agents,
• • aldehydes,
• • Aliphatic paraffin sulfochlorides,
• • synthetic tanning agents (syntans) based on phenol derivatives,
• • Polymer tanning agents (resin tanning agents)

bitter substances:

Bitter substances refer to all chemical compounds that have a bitter taste. They are not a chemically uniform group, but are only distinguished by the fact that they taste bitter. The following bitter substances are only examples and are not listed in full. On the basis of his general specialist knowledge, the person skilled in the art can easily name further possible bitter substances.

Examples of suitable bitter substances:

• • Lactucopicrin is found in chicory and all lettuce.
• • Cynarin is found in artichokes.
• • Glucosinolates are found in rapeseed oil.
• • Lactucin is found in iceberg lettuce.
• • Premarrubiin and Marrubiin
• • Naringin in grapefruit and pomelos

Color pigments:

Dyes, colored pigments, white pigments, fluorescent pigments and phosphorescent pigments (phosphorus) can be added to the topical medicinal products according to the invention in a wide variety of ways. Chalk, talc, montmorillonite, clay minerals, paper, paper-like materials and/or titanium dioxide, including black titanium dioxide, are preferred.

Plant extracts:

Plant extracts are extracts from plants used in cosmetics. The list of plant extracts below is exemplary and not exhaustive. The person skilled in the art can easily name further possible plant extracts.

Examples of suitable plant extracts:

• • African Copal bark CO ₂ -se extract
• • Angelica root CO ₂ -se extract
• • Antimicrobial Blend
• • Arnica blossom CO ₂ -to extract, 4% sesquiterpene lactones
• • Beard lichen CO ₂ -to extract, water-dispersible, 4% usnic acids
• • Borage seed CO ₂ -to extract
• • Butter CO ₂ se extract, dest. type
• • Butter CO ₂ -se Extract, Crist. Type
• • Chili CO ₂ -to extract, 10% capsaicinoids
• • Chili CO ₂ -to extract, 5% capsaicinoids
• • Turmeric Xanthorrhiza CO ₂ -se Extract
• • Dill seed CO ₂ -se extract, carvone type
• • Dill seed CO ₂ -se extract, Dillapiol type
• • Peanut CO ₂ -se Extract
• • Fennel CO ₂ -se extract, bitter type
• • Flavoxan 14, rosemary antioxidant formulation

Foam Inhibitors and Defoamers:

• • Silicone oils with silica particles
• • Mono- and diglycerides of fatty acids
• • Polydimethylsiloxane (Simethicone®, E900)
• • Tri-n-butyl phosphate
• • Tri-isobutyl phosphate
• • Thermo-oxidized soybean oil esterified with MDG (mono- and diglycerides).

• - der amerikanischen Patentanmeldung US 2012/0258150 A1 , Seiten 4 bis 6, TABLE 1, Seite 7, Absatz [0071], bis Seite 9, Absatz [00 88] Ende,
• - der deutschen Patentanmeldung DE 10 2012 214 622 A1 , Seite 4, Absatz [0016], bis Seite 16, Absatz [0039],
• - dem europäischen Patent EP 1 235 546 B1 , Seite 7, Absatz [0016], bis Seite 9, Absatz [0025] Ende, Seite 9, Absätze [0027] bis [0030], Seite 9, Absatz [0033], bis Seite 14, [0055], sowie aus
• - dem deutschen Gebrauchsmuster DE 20 2014 010 286 U1 , Seite 4, Absatz [0031], bis Seite 8, Absatz [0066].

bekannt.Examples of further suitable ingredients D for the topical medicaments according to the invention are from

• - the American patent application US2012/0258150A1 , pages 4 to 6, TABLE 1, page 7, paragraph [0071], to page 9, paragraph [00 88] end,
• - the German patent application DE 10 2012 214 622 A1 , page 4, paragraph [0016], to page 16, paragraph [0039],
• - the European patent EP 1 235 546 B1 , page 7, paragraph [0016], to page 9, paragraph [0025] end, page 9, paragraphs [0027] to [0030], page 9, paragraph [0033] to page 14, [0055], and from
• - the German utility model DE 20 2014 010 286 U1 , page 4, paragraph [0031], to page 8, paragraph [0066].

known.

The topical medicaments according to the invention can contain customary and known ionic and/or non-ionic surfactants as ingredients D (cf. Römpp Lexikon Lacke und Druckfarben, Georg Thieme Verlag, Stuttgart, 1998, keyword “Tenside”). However, it is a particular advantage of the topical medicaments according to the invention that in most cases they manage without surfactants, in particular without ionic surfactants.

The proportion of ingredients D in the topical medicaments according to the invention can vary very widely and can thus be excellently adapted to the respective intended use. Preferably, a given topical preparation contains, based on its total amount, from 0.01% to 70% by weight, preferably from 0.01% to 60% by weight and in particular 0.01% by weight of 50 % by weight of ingredients D.

The topical medicaments according to the invention can contain other pharmaceuticals for special applications. Examples of suitable pharmaceuticals can be found in the GELBEN LISTE PHARMAINDEX.

The topical medicaments according to the invention preferably have a pH between 3 and 7, preferably between 4.5-6.5 and in particular between 5-5.5, in particular in order not to damage the acid protection of the skin. In special cases, the topical medicaments according to the invention can also have a pH value >7.

According to the invention, the topical medicaments according to the invention are evident in the form of powders, solids, gels, creams, ointments, lotions, drops, sprays, metered dose aerosols, gargling solutions, lozenges, enemas, enemas, foams, release materials, coatings and coating materials on and/or in release materials, sponges, textile fabrics, face masks, gauze and plasters and prepared on and/or in roll-on pens, dispensers and medical devices. Again, this list is not final, but exemplary. Other configurations can also be used, particularly in special cases.

The topical medicaments according to the invention are produced according to the method according to the invention. At least one type of particle A is mixed with at least one type of particle B and/or at least one type of particle C and the resulting mixture is homogenized. The resulting homogenized mixture (AB), (AC) or (ABC) is then preferably processed into powders, solids, granules, gels, creams, ointments, lotions, drops, sprays, metered dose aerosols, gargling solutions, lozenges, enemas, enemas, suppositories or foams and/or applied onto and/or into textile fabrics, face masks, gauze, poultices, sanitary napkins, tampons, plasters, medical devices and/or release materials.

In a preferred embodiment, at least one type of particle A is mixed with at least one type of particle B and/or at least one type of particle C and/or at least one ingredient D and the resulting mixture (ABC), (ABD), ( ACD) or (ABCD), after which the homogenized mixture is processed as described above.

If aqueous topical medicaments according to the invention are produced according to the method according to the invention, it proves to be an advantage if water containing carbon dioxide is used because the carbon particles A are wetted better as a result. The carbon dioxide can be dissolved in the water, optionally working at overpressure, or it can be blown or bubbled through the water.

For the process according to the invention, the customary and known systems, units, apparatus, dosing techniques and measuring techniques are used, as are customarily used in the field of pharmaceuticals.

The topical medicaments according to the invention can be used in many different ways in medicine.

For example, the topical medicaments according to the invention can be used in the appropriate administration form for the treatment of the diseases listed in compilation 1. Set 1: L00-L08 skin and subcutaneous infections code Description Disease names (synonyms) L00 Staphylococcal scalded skin syndrome Staphvlococcal scalded skin syndrome (dermatitis exfoliativa neonatorum, pemphique acutus neonatorum) L01 impetigo Impetiqo contagiosa, folliculitis superficialis, impetiqinisation L02 Skin abscesses, boils and carbuncles Skin abscess, boil (furunculosis), carbuncle (pus bump) L03 phlegmon e Phleqmone, acute lymphanqitis, nail infection (onychia, paronychia, perionychia), facial phlegmon. omphalitis, cellulitis L04 Acute lymphadenitis Acute lymphadenitis, lymph node abscess L05 Pilonidal cyst Pilonidal cyst (pilonidal fistula, pilonidal sinus, coccyx sinus. coccyx cyst) L06 L07 not forgiven L08 Other local infections of the skin and subcutaneous tissue Pvoderma, purulent dermatitis, septic dermatitis, suppurative dermatitis, erythrasma L10-L14 Bullous dermatoses code Description Disease names (synonyms) L10 pemphigus diseases Pemphigus vulqaris, Pemphiques veqetans, Pemphiques foliaceus, Brazilian pemphique (Fogo selvaqem), Pemphique erythematosus, Senear-Usher syndrome, Drug-induced pemphique L11 Other acantholytic dermatoses Acquired follicular keratosis, transient acantholytic dermatosis (Grover's transient acantholytic dermatosis) L12 pemphigoid diseases Bullous pemphigoid, Cicatricial pemphigoid, Beniqne's mucosal pemphigoid, Chronic bullous dermatosis of childhood Acquired epidermolysis bullosa, Linear IqA dermatosis L13 Other bullous dermatoses Dermatitis herpetiformis (dermatitis herpetiformis Duhring), pustulosis subcornealis (pustulosis subcornealis Sneddon-Wilkinson) L14* Bullous dermatoses in diseases classified elsewhere - L20-L30 dermatitis and eczema code Description Disease names (synonyms) L20 Atopic (endogenous) eczema Atopic eczema (endogenous eczema, allergic eczema, intrinsic eczema, endogenous cradle cap, neurodermatitis, neurodermatitis atopica, neurodermatitis diffusa), Pruriqo Besnier L21 Seborrheic eczema Seborrheic eczema, seborrhoea capitis, seborrheic cradle cap. Seborrheic eczema in children L22 diaper rash Diaper dermatitis, psoriasiform diaper dermatitis, diaper rash, diaper erythema L23 Allergic contact dermatitis Allergic contact dermatitis (allergic contact eczema), nickel allergy L24 Toxic contact dermatitis Toxic contact dermatitis (non-allergic contact dermatitis, toxic contact dermatitis, irritant contact dermatitis), acne venenata (contact acne), chloracne, olacne L25 Unspecified contact dermatitis baker's dross L26 Exfoliative dermatitis Exfoliative dermatitis. Pityriasis rubra (Pityriasis rubra Hebra) L27 Dermatitis caused by substances ingested orally, enterally or parenterally - L28 Lichen simplex chronicus and prurigo Lichen simplex chronicus (Lichen Vidal), neurodermatitis chronica circumscripta, pruriqo nodularis. Pruriqo, Prurigo Hebra, Pruriqo mitis, Urticaria papulosa L29 pruritus Pruritus ani, pruritus scrotalis, pruritus vulvae, pruritus anogenitalis L30 Other dermatitis Nummular eczema. Dyshidrosis (Pompholyx), Candida mycid (Levurid), Dermatophytid, Eczematid, Eczematoid dermatitis. Infectious dermatitis, superinfected eczema, intertriquinal eczema, pityriasis alba faciei L40-L45 Papulosquamous skin diseases code Description Disease names (synonyms) L40 psoriasis psoriasis vulgaris. Nummulular psoriasis, generalized pustular psoriasis, impetiqo herpetiformis, pustular psoriasis Zumbusch, acrodermatitis continua suppurativa (acrodermatitis continua suppurativa Hallopeau), pustular psoriasis palmoplantaris, psoriasis guttata, psoriatic arthropathy, psoriasis inversa L41 parapsoriasis Pityriasis lichenoides et varioliformis acuta (Pityriasis lichenoides et varioliformis acuta Mucha-Habermann), parapsoriasis quttata, papulosis lymphomatoides, small patches parapsoriasis en plaques, large patches parapsoriasis en plaques, parapsoriasis with poikiloderma L42 pityriasis rosea Pityriasis rosea (rose lichen) L43 Planus lichen planus Hypertrophic lichen planus, pemphiqoid lichen planus, lichenoid drug reaction. Subacute lichen planus. Lichen planus tropicus L44 Other papulosquamous skin diseases Pityriasis rubra pilaris, lichen nitidus. Lichen striatus, lichen ruber moniliformis, infantile papular acrodermatitis (Gianotti-Crosti syndrome) L45* Papulosquamous skin diseases in diseases classified elsewhere - L50-L54 urticaria and erythema code Description Disease names (synonyms) L50 urticaria Allergic urticaria, idiopathic urticaria, cold urticaria, heat urticaria, urticaria factitia. Urticarial dermographism, urticaria mechanica. Cholinergic urticaria, contact urticaria, chronic urticaria, recurrent urticaria, periodic urticaria L51 Exudative erythema multiforme Nonbullous erythema multiforme (erythema multiforme minus), Bullous erythema multiforme (erythema exsudativum multiforme majus, Stevens-Johnson syndrome), Toxic epidermal necrolysis (Lyell's syndrome) L52 erythema nodosum erythema nodosum L53 Other erythematous diseases Erythema toxicum, erythema annulare centrifugum, erythema marginatum, figured chronic erythema erythroderma L54* Erythema in diseases classified elsewhere Erythema marginatum in acute rheumatic fever L55-L59 Skin and subcutaneous diseases caused by exposure to radiation code Description Disease names (synonyms) L55 Acute solar dermatitis Acute solar dermatitis (sunburn) L56 Other acute skin changes caused by ultraviolet rays Phototoxic drug reaction, Photoallergic drug reaction, Phototoxic contact dermatitis, Berloque dermatitis, Solar urticaria. Polymorphic light eruption L57 Skin changes due to chronic exposure to non-ionizing radiation Actinic keratosis, (keratosis senilis, keratosis solaris), actinic reticuloid, cutis rhomboidalis nuchae, poikilodermia reticularis (poikilodermia reticularis civatte), cutis laxa senilis (senile actinic elastosis, elastosis senilis), radiation qranuloma, country skin, sailor skin L58 radiodermatitis acute radiodermatitis, chronic radiodermatitis L59 Other diseases of the skin and subcutaneous tissue caused by exposure to radiation Ervthema ab iqne, Chronic Heat Damage L60-L75 Skin appendage diseases code Description Disease names (synonyms) L60 diseases of the nails Unguis incarnatus (ingrown nail), onycholysis, onychogryposis (onychogryphosis), nail dystrophy, Beau Reil transverse furrows, yellow nail syndrome (yellow nail syndrome) L61 not forgiven - L62* Diseases of the nails in diseases classified elsewhere - L63 Alopecia areata Alopecia cranialis totalis (alopecia totalis), alopecia universalis, ophiasis L64 Alopecia androgenetica Male-type alopecia, drug-induced androgenetic alopecia L65 Other hair loss without scarring Telogen effluvium, anagen effluvium, alopecia mucinosa Pinkus (Alopecia mucinosa) L66 Scarred alopecia (hair loss with scarring) Pseudopelade Brocg, lichen planopilaris, lichen planus follicularis, folliculitis decalvans, folliculitis et perifolliculitis capitis abscedens et suffodiens Hoffmann (folliculitis et perifolliculitis capitis abscedens et suffodiens), atrophodermia vermiculata, folliculitis uterythematosa reticulata, ulerythema acneiforme L67 Hair color and hair shaft abnormalities Trichorrhexis nodosa, canities, premature graying, heterochromia of hair, poliosis, acquired circumscripta poliosis, fragilitas crinium L68 hypertrichosis Increased hair growth, hirsutism, hypertrichosis lanuginosa acguisita, localized hypertrichosis, polytrichia L69 not forgiven - L70 acne Acne vulgaris, acne conglobata, acne varioliformis, acne necroticans miliaris, acne tropica, acne infantum, acne excoriée des jeunes filles L71 rosacea Perioral dermatitis, rhinophyma L72 Follicular cysts of the skin and subcutaneous tissue Epidermal cyst, trichilemmal cyst, atheroma, pilar cyst, steatocystoma multiplex L73 Other diseases of the hair follicles Acne keloid (folliculitis sclerotisans nuchae), pseudofolliculitis barbae, hidradenitis suppurativa, folliculitis barbae L74 Diseases of the eccrine sweat glands Miliaria rubra, Miliaria cristallina. Miliaria profunda, miliaria tropica, anhidrosis, hypohidrosis L75 Diseases of the apocrine sweat glands Bromhidrosis, Chromhidrosis, Apocrine Miliaria, Fox-Fordyce disease L80-L99 Other skin and subcutaneous diseases Code e Description Disease names (synonyms) L80 vitiligo vitiligo L81 Other skin pigmentation disorders Post-inflammatory hyperpigmentation, chloasma (melasma), ephelides (freckles), cafe au lait spots, lentigo, leukoderma, pigmentary purpura. Angioma serpiginosum, essential telangiectasia, tattoo L82 Seborrheic keratosis Seborrheic keratosis, dermatosis papulosa nigra, Leser-Trélat syndrome L83 Acanthosis nigricans Acanthosis nigricans, papillomatosis confluens et reticularis (Papillomatosis confluens et reticularis Gougerot-Carteaud) L84 Corns and corn (skin) calluses Corns, calluses, callus, clavus L85 Other epidermal thickening g Acquired ichthyosis, Acquired palmoplantar keratosis (Acquired palmoplantar keratoma), Punctual keratosis (Palmoplantar keratosis). Xerosis cutis (xeroderma), Cornu cutaneum. epidermal thickening L86* Keratoma in diseases classified elsewhere - L87 Disorders of transepidermal elimination Hyperkeratosis follicularis et parafollicularis in cutem penetrans (Hyperkeratosis follicularis et parafollicularis in cutem penetrans Kvrle. Hyperkeratosis follicularis penetrans), reactive perforating collagenosis, elastosis perforans serpiqinosa L88 pyoderma gangrenosum Pyoderma qanqraenosum Ulcerative dermatitis, Phaqedenic pyoderma L89 pressure ulcer Decubitus, pressure sore, ulcer L90 Atrophic skin diseases Lichen sclerosus et atrophicus, anetoderma, atrophodermia idiopathica, acrodermatitis chronica atrophicans Herxheimer, scars and fibrosis of the skin, striae cutis atrophicae L91 Hypertrophic skin diseases Hypertrophic scar, scar keloid L92 Granulomatous diseases of the skin and subcutaneous tissue Granuloma annulare (granuloma annulare perforans), necrobiosis lipoidica, granuloma faciale, (granuloma eosinophilicum faciei), foreign body granuloma L93 lupus erythematosus Discoid lupus erythematosus, subacute cutaneous lupus erythematosus, deep lupus erythematosus, lupus panniculitis L94 Other localized connective tissue diseases Sclerodermia circumscripta (morphea localized scleroderma), linear scleroderma (band-shaped scleroderma, scleroderma en coup de sabre), calcinosis cutis, sclerodactyly, Gottron's papules, poikilodermia atrophicans vascularis (poikilodermia atrophicans vascularis Jacobi), Ainhum L95 Vasculitis not elsewhere classified confined to the skin Livedo vasculitis, capillaritis alba, erythema elevatum et diutinum L96 not forgiven - L97 Ulcus cruris, not elsewhere classified Leg Ulcer L98 Other skin and subcutaneous disorders, not elsewhere classified Granuloma pediculatum (granuloma pγoqenicum), dermatitis factitia (neurotic excoriation), acute febrile neutrophilic dermatosis (Sweet's syndrome), eosinophilic cellulitis (Wells' syndrome), tropic ulcer, mucinosis of the skin, focal mucinous, lichen mvxoedematosus L99* Other skin and subcutaneous disorders in diseases classified elsewhere Cutaneous amyloidosis (lichen amyloidosus macular amyloidosis)

• - Hautpilze,
• - Nagelpilze und Verfärbungen und Nagelbettentzündungen,
• - Akne,
• - Haarausfall,
• - Herpes,
• - Allergischer Schnupfen, Rhinitis,
• - Nesselsucht,
• - Scheidenpilz,
• - Verbrennungen der Haut,
• - starke allergische Hautreaktionen,
• - Entzündungen und
• - Ersatz von Voltaren und anderen Schmerzmitteln bei Kniebeschwerden, Arthrose, Gonoarthrose, Hüftbeschwerden, Polyarthritis und Morbus Bechterew.

Other indications, possibly already mentioned above, are

• - skin fungi,
• - nail fungus and discoloration and nail bed inflammation,
• - acne,
• - hair loss,
• - herpes,
• - allergic cold, rhinitis,
• - hives,
• - vaginal thrush,
• - skin burns,
• - severe allergic skin reactions,
• - Inflammation and
• - Replacement of Voltaren and other painkillers for knee problems, arthrosis, gonoarthrosis, hip problems, polyarthritis and Bechterew's disease.

Other indications are the rheumatic forms, which include very different clinical pictures that are divided into four main groups according to their cause.

A further subdivision is made within these groups. The following classification scheme currently applies (see compilation 2). Here the topical drug according to the invention is used for cortisone replacement treatment.

Compilation 2: Rheumatic types

• • Inflammatory rheumatic diseases (due to the autoimmune system):
  • o Rheumatoid arthritis (chronic polyarthritis)
    • • Rheumatic fever (also called acute articular rheumatism, polyarthritis rheumatica acuta and rheumatism acuteus verus ^[9] ) has been clearly differentiated from this since 1953 ^[10 ]
  • o Juvenile idiopathic arthritis
  • ◯ Spondyloarthritis
    • ▪ Ankylosing spondylitis (Bechterew's disease)
    • ▪ Psoriatic arthritis
    • ▪ Enteropathic arthritis (accompanying intestinal diseases such as ulcerative colitis)
    • ▪ Reactive arthritis
    • ▪ undifferentiated spondyloarthritis
  • ◯ Collagen diseases (connective tissue diseases):
    • ▪ Lupus erythematosus
    • ▪ Systemic sclerosis
    • ▪ Sjogren's syndrome
    • • Polymyositis and dermatomyositis
    • ▪ Mixed collagenosis
  • ◯ Vasculitides (diseases with vascular inflammation)
  • ◯ Polymyalgia rheumatica
• • Degenerative ("wear-related") rheumatic diseases:
  • ◯ Osteoarthritis
  • ◯ Tendonitis
• • Metabolic disorders associated with rheumatic complaints:
  • ◯ Gout and other crystal deposition diseases
  • ◯ Hemochromatosis (iron metabolism disorder)
• • Rheumatic non-inflammatory diseases of the soft tissues with symptoms such as pain in the muscles and tendons:
  • ◯ Fibromyalgia (non-inflammatory soft tissue rheumatism, “soft tissue rheumatism”)
• • Rheumatoid diseases

The present invention is explained in more detail below using examples and comparative tests. The examples and comparative tests serve to illustrate the invention and are not limiting.

examples

example 1

Topical Drug of the Invention Elimination of chemotherapeutic agents secreted through the skin

• - 15 Gew.-% von unter Stickstoff bei 25 °C mechanochemisch vorbehandelte, laut Röntgenemissionsspektroskopie schwermetallfreie sowie von persistenten organischen Schadstoffen (POP), polycyclischen aromatischen Kohlenwasserstoffen (PAK), faserförmigen Anteilen und Meso- und Makroporen freie Aktivkohlepartikel A eines Kohlenstoffgehalts von 99,1 Mol-% und einer elektronenmikroskopisch ermittelten Teilchengröße im Bereich von 300 nm bis 800 nm,
• - 0,5 Gew.-% Dikaliumhydrogenphosphat als Puffer D,
• - 0,05 Gew.-% Simethicone® E900 Schauminhibitor D,
• - 3,0 Gew.-% Magnesiumaluminiumsilikat,
• - 3,0 Gew.-% Zitronensäure kristallin,
• - 2 Gew.-% Hydroxyacetophenon,
• - 5,0 Gew.-% Xanthangummi einer mittleren Teilchengröße d₅₀ von 100 µm und
• - 10 Gew.-% Hexandiol in
• - 61,45 Gew.-% destilliertes Wasser

unter sterilen Bedingungen und Durchperlen von Kohlendioxid dispergiert. Die resultierende erfindungsgemäße medizinische Salbe wird unter leichtem Rühren und Unterdruck entgast und in sterile Spender abgefüllt. Die erfindungsgemäße medizinische Salbe erweist sich als lagerstabil. Es werden weder ein Aufschwimmen noch ein Absetzen von Bestandteile beobachtet.In a hospital pharmacy, an ointment for oncological use is made by

• - 15 wt. 1 mol% and a particle size determined by electron microscopy in the range from 300 nm to 800 nm,
• - 0.5% by weight of dipotassium hydrogen phosphate as buffer D,
• - 0.05% by weight of Simethicone® E900 foam inhibitor D,
• - 3.0% by weight of magnesium aluminum silicate,
• - 3.0% by weight of crystalline citric acid,
• - 2% by weight of hydroxyacetophenone,
• - 5.0% by weight of xanthan gum with an average particle size d ₅₀ of 100 μm and
• - 10% by weight of hexanediol in
• - 61.45% by weight of distilled water

dispersed under sterile conditions and bubbling with carbon dioxide. The resulting medical ointment according to the invention is degassed with gentle stirring and reduced pressure and filled into sterile dispensers. The medicinal ointment according to the invention proves to be storage-stable. Neither floating nor settling of components is observed.

Cancer patients undergoing chemotherapy in the hospital have very strong drugs entering their bodies. These drugs and their metabolites are partially excreted. This happens, among other things, through the skin. This means that not only the skin of the cancer patients is damaged, but also those around them and the caregivers.

Under medical supervision, twelve cancer patients are divided into three groups of four patients each. In two patients from the first group who are treated with cisplatin, the skin in the armpits and skin folds is treated with the medicinal ointment according to the invention. After exposure to the medicinal ointment for 10 hours at a time, it is washed off. For comparison, the skin of two patients in the group is treated with a conventional skin ointment, which is also washed off after 10 hours.

The second group of cancer patients treated with doxorubicin is treated in the same way.

The third group of cancer patients treated with vinblastine sulfate is treated in the same way.

The skin of the twelve patients is then examined. It is found that the skin of the cancer patients treated with the medicinal ointment according to the invention is not irritated or damaged and that drugs and metabolites can no longer be detected on the skin.

Comparative test V1

Attempt to produce a medicinal ointment for absorbing and/or breaking down chemotherapeutic agents secreted through the skin

An attempt is made to repeat the production process of example 1 with activated carbon Cl 77266 (carbon black) instead of the activated carbon particles A. However, stable medicinal ointment is not obtained because carbon black partly floats and partly settles. The resulting mixture is therefore not suitable for medicinal ointment.

Comparative test V2

Attempt to produce a medicinal ointment for absorbing and/or breaking down chemotherapeutic agents secreted through the skin

An attempt is made to use the production process of Example 1 with that from the German patent application DE 10 2017 010 930 A1 and the corresponding international patent application WO 2019/101357 A1 known carbon nanoparticles an average particle size d ₅₀ = 650 ± 200 nm instead of the activated carbon particles A to repeat. It is found that, in contrast to the comparison test C1, a homogeneous paste is initially formed, but this partially separates after prolonged storage. Therefore, the resulting ointment is not suitable for treatment. A storage-stable ointment is obtained only when the content of the carbon nanoparticles is reduced to 3% by weight.

example 2

Topical drug according to the invention for the preventive protection of nursing staff who come into contact with chemotherapeutic agents.

The cleansing/protecting paste is used as a preventive medicine to protect the skin from chemicals such as chemotherapy drugs to absorb them so they cannot penetrate the skin barrier.

• - 30 Gewichtsteile von unter Argon bei 25 °C mechanochemisch vorbehandelte, laut Röntgenemissionsspektroskopie schwermetallfreie sowie von persistenten organischen Schadstoffen (POP), polycyclischen aromatischen Kohlenwasserstoffen (PAK), faserförmigen Anteilen und Meso- und Makroporen freie Aktivkohlepartikel A eines Kohlenstoffgehalts von 99,3 Mol-% und einer elektronenmikroskopisch ermittelten Teilchengröße im Bereich von 400 nm bis 900 nm,
• - 50 Gewichtsteile von Bienenwachspartikeln D einer mittleren Teilchengröße d₅₀ von 200 µm,
• - 2 Gewichtsteile nanokristalliner Cellulose (CNC) C einer mittleren Teilchengröße d₅₀ von 650 ± 100 nm,
• - 0,5 Gewichtsteile Dikaliumhydrogenphosphat als Puffer D und
• - 0,05 Gewichtsteile Simethicone® E900 Schauminhibitor D

in 40,45 Gewichtsteilen Wasser D unter sterilen Bedingungen und Durchperlen von Kohlendioxid dispergiert. Die resultierende pastöse Salbe wird unter leichtem Rühren und Unterdruck entgast und in sterile Spender abgefüllt.A pasty ointment is produced as a protective film by

• - 30 parts by weight of activated carbon particles A, mechanochemically pretreated under argon at 25 °C and free according to X-ray emission spectroscopy of heavy metals and persistent organic pollutants (POP), polycyclic aromatic hydrocarbons (PAH), fibrous components and meso- and macropores, with a carbon content of 99.3 mol- % and a particle size determined by electron microscopy in the range from 400 nm to 900 nm,
• - 50 parts by weight of beeswax particles D with an average particle size d ₅₀ of 200 µm,
• - 2 parts by weight of nanocrystalline cellulose (CNC) C with an average particle size d ₅₀ of 650 ± 100 nm,
• - 0.5 part by weight of dipotassium hydrogen phosphate as buffer D and
• - 0.05 parts by weight of Simethicone® E900 foam inhibitor D

dispersed in 40.45 parts by weight of water D under sterile conditions and bubbling with carbon dioxide. The resulting pasty ointment is degassed with gentle stirring and reduced pressure and filled into sterile dispensers.

In cancer patients who have to undergo chemotherapy as described in example 1, very strong drugs enter the body. These drugs and their metabolites are used in part eliminated again. This happens, among other things, through the skin. This means that the environment of the cancer patients and especially the nursing staff are damaged in the event of contact. Before and/or during the therapeutic intervention and during the care of the patients, the hands of the nursing staff are treated with the ointment. The ointment forms a protective film that absorbs drugs and metabolites. After care and/or when care is interrupted, it is washed off. It shows that the nursing staff's skin is not irritated or damaged and that drugs and metabolites can no longer be detected on the skin.

Example 3

Topical drug according to the invention for the preventive treatment of calcinosis cutis.

Calcinosis cutis refers to deposits within the skin consisting of calcium phosphate with the formation of calcium salt crystals. The resulting swelling can be accompanied by local inflammation, pain and/or plaque breakthrough. As a treatment, the plaques are surgically removed.

• - 30 Gewichtsteilen von unter Argon bei 25 °C mechanochemisch vorbehandelten, laut Röntgenemissionsspektroskopie schwermetallfreien sowie von persistenten organischen Schadstoffen (POP), polycyclischen aromatischen Kohlenwasserstoffen (PAK), faserförmigen Anteilen und Meso- und Makroporen freien Aktivkohlepartikeln A eines Kohlenstoffgehalts von 99,2 Mol-% und einer elektronenmikroskopisch ermittelten Teilchengröße im Bereich von 400 nm bis 900 nm,
• - 50 Gewichtsteilen von Bienenwachspartikeln D einer mittleren Teilchengröße d₅₀ von 200 µm,
• - 2 Gewichtsteilen nanokristalliner Cellulose (CNC) C einer mittleren Teilchengröße d₅₀ von 650 ± 100 nm,
• - 0,5 Gewichtsteilen Dikaliumhydrogenphosphat als Puffer D,
• - 0,05 Gewichtsteilen Simethicone® E900 Schauminhibitor D,
• - 10 Gewichtsteilen Hexahydroxycyclohexanhexaphosphorsäureestersalz-Nanopartikel D (Natriumsalz der Phytinsäure) einer mittleren Teilchengröße von 650 ± 150 nm und
• - 1 Gewichtsteil Polyethylenglykol (PEG) zur Öffnung der Hautporen

in 40,0 Gewichtsteilen Wasser D unter sterilen Bedingungen und Durchperlen von Kohlendioxid dispergiert. Die resultierende pastöse Salbe wird unter leichtem Rühren und Unterdruck entgast und in sterile Spender abgefüllt.To avoid inflammation and against further deposits, an ointment is made

• - 30 parts by weight of activated carbon particles A mechanochemically pretreated under argon at 25 °C and according to X-ray emission spectroscopy free of heavy metals and persistent organic pollutants (POP), polycyclic aromatic hydrocarbons (PAH), fibrous components and meso- and macropores with a carbon content of 99.2 mol- % and a particle size determined by electron microscopy in the range from 400 nm to 900 nm,
• - 50 parts by weight of beeswax particles D with an average particle size d ₅₀ of 200 µm,
• - 2 parts by weight of nanocrystalline cellulose (CNC) C with an average particle size d ₅₀ of 650 ± 100 nm,
• - 0.5 parts by weight of dipotassium hydrogen phosphate as buffer D,
• - 0.05 parts by weight of Simethicone® E900 foam inhibitor D,
• - 10 parts by weight of hexahydroxycyclohexanehexaphosphoric acid ester salt nanoparticles D (sodium salt of phytic acid) with an average particle size of 650 ± 150 nm and
• - 1 part by weight of polyethylene glycol (PEG) to open skin pores

dispersed in 40.0 parts by weight of water D under sterile conditions and bubbling with carbon dioxide. The resulting pasty ointment is degassed with gentle stirring and reduced pressure and filled into sterile dispensers.

The ointment is applied to and around the affected areas in a group of ten patients with calcinosis cutis under medical supervision and effectively prevents inflammation and further deposits in the skin.

Example 3

Medicinal lotion according to the invention for the treatment of neurodermatitis

• - 150 Gewichtsteilen von unter Stickstoff bei 25 °C mechanochemisch vorbehandelten, laut Röntgenemissionsspektroskopie schwermetallfreien sowie von persistenten organischen Schadstoffen (POP), polycyclischen aromatischen Kohlenwasserstoffen (PAK), faserförmigen Anteilen und Meso- und Makroporen freien Aktivkohlepartikeln A eines Kohlenstoffgehalts von 99,4 Mol-% und einer elektronenmikroskopisch ermittelten Teilchengröße im Bereich von 400 nm bis 900 nm,
• - 10 Gewichtsteilen von Cerabellina einer mittleren Teilchengröße d₅₀ von 200 µm,
• - 1 Gewichtsteil nanokristalliner Cellulose (CNC) einer mittleren Teilchengröße d₅₀ von 650 ± 100 nm,
• - 15 Gewichtsteilen Ethanol,
• - 5 Gewichtsteilen Panethol,
• - 0,5 Gewichtsteile Cinnamomum Zeylanicum Leaf Oil,
• - 0,1 Gewichtsteile Polyethylenglykol (PEG) und
• - 100 Gewichtsteilen Wasser

unter sterilen Bedingungen hergestellt und in Flaschen abgefüllt. Zur Anwendung wird die medizinische Lotion bei zehn Patienten unter der Aufsicht eines Dermatologen auf die befallenen Hautpartien aufgetragen und 20 Minuten lang einwirken gelassen. Danach wird die Lotion mit lauwarmem Wasser abgespült. Die Behandlung wird während einer Woche einmal täglich wiederholt. Dadurch die Symptome der Patienten für mehrere Wochen beseitigt. Außerdem führt das Ausbleiben des quälenden Juckreizes dazu, dass sich die Patienten nicht mehr durch Kratzen an den befallenen Stellen selbst verletzen.A watery lotion is made to relieve the symptoms of eczema

• - 150 parts by weight of activated carbon particles A, mechanically pretreated under nitrogen at 25 °C and, according to X-ray emission spectroscopy, free of heavy metals and persistent organic pollutants (POP), polycyclic aromatic hydrocarbons (PAH), fibrous components and meso- and macropores, with a carbon content of 99.4 mol- % and a particle size determined by electron microscopy in the range from 400 nm to 900 nm,
• - 10 parts by weight of Cerabellina with an average particle size d ₅₀ of 200 µm,
• - 1 part by weight of nanocrystalline cellulose (CNC) with an average particle size d ₅₀ of 650 ± 100 nm,
• - 15 parts by weight of ethanol,
• - 5 parts by weight panethol,
• - 0.5 parts by weight of Cinnamomum Zeylanicum Leaf Oil,
• - 0.1 part by weight of polyethylene glycol (PEG) and
• - 100 parts by weight of water

Manufactured and bottled under sterile conditions. For use, the medicinal lotion is applied to the affected skin areas of ten patients under the supervision of a dermatologist and left to act for 20 minutes. The lotion is then rinsed off with lukewarm water. The treatment is repeated once a day for a week. This eliminates the symptoms of patients for several weeks. In addition, the absence of the tormenting itching means that patients no longer injure themselves by scratching the affected areas.

example 4

Topical drug according to the invention for the treatment of arthrosis symptoms

• - 8 von unter Argon bei 25 °C mechanochemisch vorbehandelten, laut Röntgenemissionsspektroskopie schwermetallfreien sowie von persistenten organischen Schadstoffen (POP), polycyclischen aromatischen Kohlenwasserstoffen (PAK), faserförmigen Anteilen und Meso- und Makroporen freien Aktivkohlepartikeln A eines Kohlenstoffgehalts von 99,4 Mol-% und einer elektronenmikroskopisch ermittelten Teilchengröße im Bereich von 450 nm bis 850 nm,
• - 2 Gewichtsteile Bienenwachs,
• - 2 Gewichtsteile nanokristalliner Cellulose (CNC) (C) einer mittleren Teilchengröße d₅₀ von 650 ± 100 nm,
• - 0,5 Gewichtsteile Dikaliumhydrogenphosphat als Puffer (E) und
• - 0,05 Gewichtsteile Simethicone® E900 Schauminhibitor (E)

werden in 52,45 Gewichtsteilen destilliertem Wasser unter sterilen Bedingungen und Durchperlen von Kohlendioxid dispergiert. Die resultierende pastöse Salbe wird unter leichtem Rühren und Unterdruck entgast und in sterile Spender abgefüllt. Die pastöse Salbe hat eine blaustichige bis lilastichige graue Farbe. Bei dem Einmassieren zog die erfindungsgemäße Salbe samt den Aktivkohlepartikeln A in die Haut ein und hinterließ keinerlei schwarzen Reste auf der Haut.Twelve patients with severe arthrosis complaints on the hands and feet suffer chronically from intermittent, very painful swelling and deformation of the joints. The patients are therefore guaranteed under the supervision of a rheumatologist with a medicinal ointment prepared according to the method of the invention. The medicinal ointment was applied to the affected joints and limbs during acute flare-ups. The medicinal ointment according to the invention has been produced as follows:

• - 8 of activated carbon particles A mechanochemically pretreated under argon at 25 °C, according to X-ray emission spectroscopy, free of heavy metals and persistent organic pollutants (POP), polycyclic aromatic hydrocarbons (PAH), fibrous components and meso- and macropores, with a carbon content of 99.4 mol % and a particle size determined by electron microscopy in the range from 450 nm to 850 nm,
• - 2 parts by weight beeswax,
• - 2 parts by weight of nanocrystalline cellulose (CNC) (C) with an average particle size d ₅₀ of 650 ± 100 nm,
• - 0.5 part by weight of dipotassium hydrogen phosphate as buffer (E) and
• - 0.05 parts by weight of Simethicone® E900 foam inhibitor (E)

are dispersed in 52.45 parts by weight of distilled water under sterile conditions and bubbling with carbon dioxide. The resulting pasty ointment is degassed with gentle stirring and reduced pressure and filled into sterile dispensers. The pasty ointment has a bluish to purple-tinged gray color. When massaged in, the ointment according to the invention, together with the activated carbon particles A, was absorbed into the skin and left no black residue whatsoever on the skin.

In all patients, swelling and pain subside rapidly within 10 to 20 minutes. The success of the treatment lasts up to four days for all patents.

Example 5

Topical drug according to the invention for the treatment of nail fungus and nail bed inflammation

The medicinal ointment of Example 1 according to the invention is used under medical supervision for the treatment of nail fungus and nail bed inflammation in six patients. In one case the infestation of the toenails was so severe that the toenails were deformed and bent upwards by spongy, putrid-smelling excretions and deposits under the nails. The repeated treatment with the medicinal ointment according to the invention eliminates the nail fungus and the nail bed inflammation and in particular the excretions and deposits under the nails of one patient disappear.

Example 6

Topical medicament according to the invention for the treatment of allergic skin reactions caused by contact with oak processionary moths

Twenty-nine test persons are contacted with the hair of oak processionary moths in a grid in a controlled manner on the inside of their right forearms and their right wrists under medical supervision by an allergist. The allergic reactions are immediate, with symptoms, itching, and pain reported as mild by two subjects and severe by the other subjects. The exposed sites were treated with the topical drug of Example 1 of the present invention morning, noon and night. In twenty-eight subjects, the allergic reactions disappeared permanently. One subject does not respond to treatment.

QUOTES INCLUDED IN DESCRIPTION

This list of documents cited by the applicant was generated automatically and is included solely for the better information of the reader. The list is not part of the German patent or utility model application. The DPMA assumes no liability for any errors or omissions.

Patent Literature Cited

• DE 202014010286 U1 [0010, 0081]
• DE 102017010930 A1 [0011, 0104]
• WO 2019/101357 A1 [0011, 0104]
• US 2012/0258150 A1 [0052, 0081]
• US 2013/0259913 A1 [0052]
• US 2014/0026916 A1 [0054]
• US 2010/0278882 A1 [0055]
• EP 0563876 A2 [0056]
• DE 102012214622 A1 [0081]
• EP 1235546 B1 [0081]

Claims (19)

Activated carbon particles (A) mechanochemically pretreated under at least one inert gas, free of heavy metals and persistent organic pollutants (POP), polycyclic aromatic hydrocarbons (PAH), fibrous components and meso- and macropores according to X-ray emission spectroscopy, with a carbon content >99 mol% and a particle size determined by electron microscopy in the range of 100 nm to 1000 nm for use in medicine Heavy metal-free topical medicinal products containing activated carbon particles (A) with a carbon content >99 mol% and which have been mechanochemically pretreated under at least one inert gas and are free of heavy metals and persistent organic pollutants (POP), polycyclic aromatic hydrocarbons (PAH), fibrous components and meso- and macropores according to X-ray emission spectroscopy a particle size determined by electron microscopy in the range from 100 nm to 1000 nm, for use in medicine. Heavy metal-free topical drugs for use in medicine according to claim 2 for the elimination of chemotherapeutic agents that are excreted through the skin, for the preventive treatment of calcinosis cutis and for the treatment of neurodermatitis, arthrosis symptoms, nail fungus and nail bed inflammation and allergic reactions to oak processionary moths. Non-heavy metal topical drugs for use in medicine claim 2 or 3 , characterized in that the at least one inert gas is selected from the group consisting of nitrogen, helium, neon, argon and xenon. Non-heavy metal topical medicinal products for use in medicine according to any one of claims 2 until 4 , characterized in that the absence of meso- and macropores is determined by electron microscopy. Non-heavy metal topical medicinal products for use in medicine according to any one of claims 2 until 5 , characterized in that the specific internal surface area of the activated carbon particles (A) according to BET is <200 m ² / g. Non-heavy metal topical medicinal products for use in medicine according to any one of claims 2 until 6 , characterized in that they contain no organically bound halogens. Non-heavy metal topical medicinal products for use in medicine according to any one of claims 2 until 7 , characterized in that the topical medicaments contain the activated carbon particles (A), based on the respective total amount of a topical medicament, in an amount of 0.1% by weight to 50% by weight. Non-heavy metal topical medicinal products for use in medicine according to any one of claims 2 until 8th , characterized in that they additionally (B) particles with an average particle size d ₅₀ from 10 nm to <1000 µm, containing at least one type and/or consisting of at least one type of nanocrystalline and/or microcrystalline natural waxes and/or semisynthetic waxes based on natural waxes and/or biodegradable microplastics. Non-heavy metal topical drugs for use in medicine claim 6 , characterized in that the particles (B) from natural and semi-synthetic waxes using the GAS method (Gas Antisolvent Recrystallization), the PCA method (Precipitation with a Compressed Fluid Antisolvent), the PGSS method (Particles from Gas Saturated Solutions) or the RESS process (Rapid Expansion of Supercritical Solutions). Non-heavy metal topical medicinal products for use in medicine according to any one of Claims 1 until 10 , characterized in that they additionally contain (C) particles with an average particle size d ₅₀ of 10 nm to <1000 nm, containing at least one type and/or consisting of at least one type of nanocrystalline, nanofibrillar, microcrystalline and/or microfibrillar polysaccharides. Non-heavy metal topical drugs for use in medicine claim 11 , characterized in that the particles (C) from the group consisting of cellulose nanofibers (CNF), microfibrillar celluloses (MFC), microcrystalline celluloses (MCC), nanofibrillar polysaccharides (NFP), nanocrystalline celluloses (CNC) and bacterial nanocelluloses (BNC) , waste from paper mash from paper manufacture and fibers, as well as particles from used textiles, are selected. Non-heavy metal topical drugs for use in medicine claim 11 or 12 , characterized in that the particles (C) have an average particle size d ₅₀ = 650 ± 200 nm. Non-heavy metal topical medicinal products for use in medicine according to any one of claims 2 until 13 , characterized in that they additionally (D) at least one ingredient selected from the group consisting of water, phyllosilicates, ground clays, Bolus Americus clays, healing clays, nut shells, willow bark, Lapacho healing bark, silica, pumice stones, geopolymers, amber, Precious stones, trace elements and neutral inorganic salts, beta-glucans, glutathione, albumin, xylan, phytates, complexing agents, antioxidants, radical scavengers, menthol, caffeine, theine, papain, esculin semihydrate, carotenoids, lecithins, abscinic acid, cyanidin, guanidin, urea, thiourea, Fillers, solvents, humectants, solubilizers, nonionic wetting agents, buffers, thickeners, binders, coating agents, disintegrants, disintegrants, lubricants, lubricants, mold release agents, flow regulators, antioxidants, preservatives, sweeteners, flavorings, absorption accelerators, alkali sizing agents, acidifiers, neutralizing agents, foam inhibitors and defoamers, dyes, color pigments, oxidizing agents, reducing agents, stabilizers, propellants, opacifiers, pearlescent agents, denaturants, plasticizers, minerals, vitamins, micelles, superabsorbents, moisturizing substances, oils, fragrances, flavorings, perfumes, moisturizers , moisturizers, active ingredients for skin care, deodorizing active ingredients, film formers, gel formers, tanning agents, tanning agents, tanning extracts, bitter substances, plant extracts, honey, colostrum, cytostatics, antibodies, immunoglobulins, essential and non-essential amino acids and fats, hyaluronic acid, aloe vera gel, liposomes , alkylene glycols, polyalkylene ether glycols, proteins, peptides, carbohydrates, lipids, nucleic acids, nucleic acid fragments, antiviral compounds, anti-inflammatory compounds, antibiotics, cell differentiation agents, analgesics, anesthetics agents, anesthetics, contrast agents, enzymes, cytokines, antihistamines, immunomodulators, hemostatic agents, hormones, angiogenic and antiangiogenic agents, neurotransmitters, therapeutic oligonucleotides, viral particles, growth factors, retinoids, cell adhesion factors, extracellular matrix glycoproteins, osteogenic factors, antibodies, antigens, steroids, analgesics , potassium sulfate, royal jelly, propolis, encapsulated fragrances, nutrients, hexahydroxycyclohexane hexaphosphoric acid ester salt nanoparticles and surfactants. Non-heavy metal topical medicinal products for use in medicine according to any one of claims 2 until 14 , characterized in that they are available as powders, solids, gels, creams, ointments, lotions, drops, sprays, metered dose aerosols, gargling solutions, lozenges, enemas, enemas, foams and release materials and as coatings on textile fabrics, face masks, bandages, foam plasters, toiletry items, compresses, pads, tampons and on and in medical devices and roll-on pens. Non-heavy metal topical drugs for use in medicine according to a . the claims 2 until 15 , characterized in that its pH is between 3 and 7. Process for the manufacture of topical medicaments for use in medicine according to any one of claims 2 until 16 , characterized in that (I) at least one type of activated carbon particles (A) is mixed with at least one type of particle (B) and/or at least one type of particle (C) and the resulting mixture is homogenized and (II) the resulting homogenized mixture (AB), (AC) or (ABC) to powders, solids, granules, gels, creams, ointments, lotions, drops, sprays, dosing aerosols, gargling solutions, lozenges, enemas, enemas, suppositories or foams and/or processed on and /or applied to textile fabrics, face masks, gauze, poultices, sanitary napkins, tampons, plasters, medical devices and/or release materials. procedure after Claim 17 , characterized in that the activated carbon particles (A) with at least one type of particles (B) and / or at least one type of particles (C) and / or min least one ingredient (D) mixed together and the resulting mixture (ABC), (ABD), (ACD) or (ABCD) homogenized. Conspicuously preparations of the topical medicaments for use in medicine according to any one of Claims 1 until 15 in the form of powders, solids, gels, creams, ointments, lotions, drops, sprays, metered dose aerosols, gargling solutions, lozenges, enemas, enemas, foams, release materials, coatings and coating materials on and/or in release materials, sponges, textile fabrics, tampons, face masks, gauze and plasters and can be prepared on and/or in roll-on pens, dispensers and medical devices.